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Abstract 
Background: In current management of type 2 diabetes (T2DM), cardiovascular and renal prevention have become 
important targets to be achieved. In this context, a joint panel of four endocrinology societies from Brazil and Portugal 
was established to develop an evidence‑based guideline for treatment of hyperglycemia in T2DM.
Methods: MEDLINE (via PubMed) was searched for randomized clinical trials, meta‑analyses, and observational 
studies related to diabetes treatment. When there was insufficient high‑quality evidence, expert opinion was sought. 
Updated positions on treatment of T2DM patients with heart failure (HF), atherosclerotic CV disease (ASCVD), chronic 
kidney disease (CKD), and patients with no vascular complications were developed. The degree of recommendation 
and the level of evidence were determined using predefined criteria.
Results and conclusions: In non‑pregnant adults, the recommended  HbA1c target is below 7%. Higher levels are 
recommended in frail older adults and patients at higher risk of hypoglycemia. Lifestyle modification is recommended 
at all phases of treatment. Metformin is the first choice when  HbA1c is 6.5–7.5%. When  HbA1c is 7.5–9.0%, dual therapy 
with metformin plus an SGLT2i and/or GLP‑1RA (first‑line antidiabetic agents, AD1) is recommended due to cardiovas‑
cular and renal benefits. If an AD1 is unaffordable, other antidiabetic drugs (AD) may be used. Triple or quadruple ther‑
apy should be considered when  HbA1c remains above target. In patients with clinical or subclinical atherosclerosis, 
the combination of one AD1 plus metformin is the recommended first‑line therapy to reduce cardiovascular events 
and improve blood glucose control. In stable heart failure with low ejection fraction (< 40%) and glomerular filtration 
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/





1 Internal Medicine Department, School of Medicine, Universidade 
Federal do Rio Grande do Sul (UFRGS), Rua Ramiro Barcelos, 2350, 4º 
Andar, Porto Alegre, RS 90035‑007, Brazil
Full list of author information is available at the end of the article
Page 2 of 30Bertoluci et al. Diabetol Metab Syndr           (2020) 12:45 
Background
As new medications have become available in recent 
years, perspectives on the management of people with 
type 2 diabetes (T2DM) have evolved into a broader 
approach in which primary and secondary cardiovascular 
and renal prevention have become important targets. The 
unique characteristics of these new antidiabetic agents, 
with proven cardiovascular (CV) and renal benefits, have 
compelled scientific societies to update their guidelines. 
In this line, the present guideline is a joint initiative of 
four societies from Portugal and Brazil: Sociedade Bra-
sileira de Diabetes (SBD), Sociedade Brasileira de Endo-
crinologia e Metabologia (SBEM), Sociedade Portuguesa 
de Diabetologia (SPD) and Sociedade Portuguesa de 
Endocrinologia, Diabetes, e Metabolismo (SPEDM).
To develop this guideline, the best evidence available 
was reviewed and the expert opinions of a Portuguese-
Brazilian panel of diabetes specialists were obtained. 
A list of statements was carefully created and scored. 
When high-quality evidence was not available from the 
literature, the panel gave opinions on a variety of clini-
cal scenarios. These opinions were captured and analyzed 
by an international voting system, which allowed con-
sensus to be reached after multiple rounds of discussion. 
The main objective of this guideline is to support the 
decision-making process in clinical practice, taking into 
account patients’ best interests and clinicians’ personal 
preferences.
Methods
The scientific societies appointed 33 specialists with exten-
sive expertise in diabetes to compose the panel. The main 
clinical topics requiring updated positions in patients with 
T2DM were heart failure (HF), atherosclerotic CV disease 
(ASCVD), chronic kidney disease (CKD), and management 
of T2DM in patients without vascular complications. The 
panel compiled a narrative review by searching MEDLINE 
(via PubMed) for randomized clinical trials, meta-analyses, 
and high-quality observational studies related to type 2 
diabetes treatment, using the MeSH terms [diabetes], [type 
2 diabetes], [cardiovascular disease], [coronary artery dis-
ease], [heart failure], and [chronic kidney disease]. When 
the results of the search did not yield enough high-qual-
ity evidence to answer a specific question or scenario, an 
expert opinion was sought: a query was sent to all panelists, 
and responses were recorded. The frequency of responses 
was analyzed and a consensus opinion was drawn up.
The degree of recommendation depended on the query, 
following the criteria that are shown in Table 1A. The level 
of evidence was determined using the same criteria in 
Table 1B. Specific criteria for atherosclerotic cardiovascular 
disease (ASCVD) are shown in Table 2 [1]. The panel chose 
to classify therapeutic options into two groups of glucose-
lowering agents: antidiabetics with proven CV or renal 
benefit (AD1) and general glucose-lowering agents (AD). 
These are specified in Table 3.
The guideline-building process was conducted as 
described elsewhere [1]. In brief, a preliminary manuscript 
outlining grades of recommendation and levels of evi-
dence was drafted. Several rounds of discussion were held 
among the panel members, who reviewed the findings and 
made suggestions. The manuscript was then returned to 
the lead author for inclusion of changes. The same proce-
dure was repeated for each of the four modules (ASCVD, 
HF, CKD, and patients without vascular complications). 
Subsequently, many other rounds of revision were done by 
request of subcommittee members. Then, the manuscript 
was presented for public consultation and discussed with 
the audience; minor adjustments were suggested. Finally, 
the consensus version of the document was submitted to 
the editorial board for final editing and proofreading.
Recommendations and summary of evidence
HbA1C target
1. In non-pregnant adult patients with T2DM, an 
HbA1c target of < 7% is recommended to reduce the 
incidence of microvascular complications.
rate (eGFR) > 30 mL/min/1.73 m2, metformin plus an SGLT‑2i is recommended to reduce cardiovascular mortality 
and heart failure hospitalizations and improve blood glucose control. In patients with diabetes‑associated chronic 
kidney disease (CKD) (eGFR 30–60 mL/min/1.73 m2 or eGFR 30–90 mL/min/1.73 m2 with albuminuria > 30 mg/g), the 
combination of metformin and an SGLT2i is recommended to attenuate loss of renal function, reduce albuminuria 
and improve blood glucose control. In patients with severe renal failure, insulin‑based therapy is recommended to 
improve blood glucose control. Alternatively, GLP‑1RA, DPP4i, gliclazide MR and pioglitazone may be considered to 
reduce albuminuria. In conclusion, the current evidence supports individualizing anti‑hyperglycemic treatment for 
T2DM.
Keywords: Diabetes treatment, Type 2 diabetes, Cardiovascular risk, Guidelines, Heart failure, Chronic kidney disease, 
Ischemic heart disease, ASCVD, Atherosclerotic disease
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I A 
Summary of evidence
• The UKPDS 33 trial [2] showed that improving glu-
cose control by reducing  HbA1c to a target of below 
7% is clearly associated with reduced microvascu-
Table 1 Class of recommendation and level of evidence
A. Class of 
recommendation 
Definition Wording in the 
text 
I There was a consensus. More than 90% of 
the panel agrees. 
Is recommended 
IIa There is a general preference in favor. 
Between 70-90% of the panel agrees. 
Should be 
considered 
IIb Agreement by the majority. Between 50-
70% of the panel agrees. 
May be 
considered 




B. Level of evidence
A  Data from more than one randomized clinical trial or one meta-
analysis of randomized clinical trials with low heterogeneity. 
B Data from meta-analyses including observational studies, a single 
randomized clinical trial, pre-specified subgroup analysis, or 
large observational studies. 
C Data from small or non-randomized studies, exploratory analyses, 
or expert opinion. 
Table 2 Definitions of atherosclerotic cardiovascular disease (ASCVD) [1]
Clinical atherosclerosis
Acute coronary syndrome: acute myocardial infarction and/or unstable angina
Stable angina or previous acute myocardial infarction
Atherothrombotic stroke or transient ischemic attack
Coronary, carotid, renal‑artery, or peripheral revascularization
Peripheral vascular insufficiency or limb amputation
Severe atherosclerotic disease (stenosis > 50%) in any vascular territory
Page 4 of 30Bertoluci et al. Diabetol Metab Syndr           (2020) 12:45 
lar complications. A total of 3867 newly diagnosed 
patients with T2DM were randomly assigned to 
intensive treatment (sulfonylurea or insulin) or con-
ventional treatment (diet alone). The aim in the 
intensive group was to attain a fasting plasma glucose 
(FPG) of less than 108 mg/dL, versus the best achiev-
able FPG with diet alone in the conventional group. 
Three aggregate endpoints were considered: (1) any 
diabetes-related endpoint (sudden death, death from 
hyperglycemia or hypoglycemia, fatal or non-fatal 
myocardial infarction, angina, heart failure, stroke, 
renal failure, any amputation, vitreous hemorrhage, 
retinopathy requiring photocoagulation, blindness, 
or cataract extraction); (2) diabetes-related death 
(death from myocardial infarction, stroke, periph-
eral vascular disease, renal disease, hyperglycemia or 
hypoglycemia, and sudden death); and (3) all-cause 
mortality. After 10 years, the median  HbA1c was 7.0% 
(interquartile range [IQR], 6.2–8.2%) in the inten-
sive group versus 7.9% (6.9–8.8%) in the conven-
tional group. For any diabetes-related endpoint, risk 
was 12% lower in the intensive group (95% CI 1–21, 
p = 0.029) than in the conventional group. The risk 
reduction in the any diabetes-related composite end-
Table 3 Types of antidiabetic agents
stnegAnoitpircseDlobmyS
AD1 Agents with demonstrated 
benefit in reducing 
cardiovascular mortality and/or 
events (3P-MACE)* and/or heart 
failure, and/or hospitalization or 
renal outcomes, besides reducing 
glycemia in type 2 diabetes. 
Sodium-glucose cotransporter 2 
inhibitors (SGLT2i): 
empagliflozin, canagliflozin, and 
dapagliflozin.  
Glucagon-like peptide-1 receptor 
agonists (GLP-1RA): liraglutide, 
semaglutide, dulaglutide, and 
exenatide long-acting release 
(LAR). 
AD Agents with proven 
cardiovascular safety and 
efficacy to reduce glycemia in 
type 2 diabetes. 
Pioglitazone. sulfonylureas  
Dipeptidyl peptidase 4 (DPP4) 
inhibitors. 
Insulin-based Different treatment strategies Basal insulin. Fixed 
treatment using insulin. combinations of insulin and a 
GLP-1RA. 
Basal-bolus insulin treatment. 
a 3P-MACE: composite of three major adverse cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, and cardiovascular death)
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point was largely attributable to a 25% risk reduction 
(95% CI 7–40, p = 0.0099) in microvascular outcome 
events.
• Similar results were seen in the ADVANCE [3] study, 
which randomized 11,140 patients with T2DM to 
undergo either standard or intensive glucose con-
trol. After a median of 5 years of follow-up, the mean 
 HbA1c level in the intensive group was 6.5% com-
pared to 7.3% in the standard-control group. Inten-
sive blood glucose control also reduced the incidence 
of major microvascular events (new or worsening 
nephropathy or retinopathy) (HR, 0.86; 95% CI 0.77 
to 0.97; p = 0.01).
• Although the landmark DCCT trial [4] was con-
ducted in type 1 diabetes (T1DM), the panel consid-
ered that the effects of lowering blood glucose and 
 HbA1c down to 7% by an intensive glucose-lowering 
regimen with insulin reinforced the target level of 
< 7% in T2DM. In DCCT, 1441 patients with T1DM 
were randomized into intensive or conventional 
treatment with insulin-based therapy, targeting an 
 HbA1c of less than 6.05%. The  HbA1c attained in the 
intensive group was around 7%. In relation to con-
ventional therapy, intensive therapy reduced retin-
opathy by 76% (primary prevention group) and 54% 
(secondary prevention group). Albuminuria was 
reduced by 39% (micro) and 54% (macro), whereas 
peripheral neuropathy was reduced by 60%.
2. In non-pregnant adult patients with T2DM, an 
HbA1c target < 7% should be considered to reduce the 
long-term incidence of macrovascular complications.
IIa B 
Summary of evidence
• Long-term post-trial observational follow-up stud-
ies [5] have shown that intensive blood glucose 
control can also decrease macrovascular compli-
cations. In the post-trial observational phase of 
UKPDS, 3277 patients with T2DM were followed 
for 5 years with no attempts to maintain previously 
assigned therapies. After the first year, no between-
group differences in  HbA1c levels remained. In the 
sulfonylurea/insulin group, relative risk reductions 
persisted at 10  years for any diabetes-related end-
point (9%, p = 0.04) and for microvascular disease 
(24%, p = 0.001). However, there were also reduc-
tions in risk of myocardial infarction (15%, p = 0.01) 
and all-cause mortality (13%, p = 0.007). In the 
metformin subgroup, significant risk reductions 
persisted for any diabetes-related endpoint (21%, 
p = 0.01), myocardial infarction (33%, p = 0.005), 
and all-cause mortality (27%, p = 0.002).
• The Epidemiology of Diabetes Interventions and 
Complications (EDIC) study was a post-trial phase 
of the DCCT trial [6] in which 93% of DCCT survi-
vors were followed. CV disease (defined as nonfatal 
myocardial infarction, stroke, death from CV dis-
ease, confirmed angina, or need for coronary-artery 
revascularization) was assessed with standardized 
measures. During a mean follow-up of 17 years, 46 
CV disease events occurred in 31 patients who had 
received intensive treatment, versus 98 events in 52 
patients who had received conventional treatment. 
Intensive treatment reduced the risk of any CV dis-
ease event by 42% (95% CI 9 to 63%; p = 0.02). The 
risk of nonfatal myocardial infarction, stroke, or 
CV death (3P-MACE) decreased by 57% (95% CI 12 
to 79%; p = 0.02). The decrease in  HbA1c during the 
DCCT study was significantly associated with the 
positive effects of intensive treatment on the risk 
of CV disease. Intensive glucose control has long-
term beneficial effects against CV risk in patients 
with T1DM as well.
3. A higher individualized HbA1c target level is rec-
ommended in frail older adults, in the presence of 
comorbidities limiting life expectancy or when hypo-
glycemia is strongly to be avoided.
I C 
Summary of evidence
• This postulation was based on expert opinion. 
There was consensus among the panelists that 
 HbA1c targets should be higher in special clinical 
situations, to lower the risk of hypoglycemia.
4. HbA1c measurements should be obtained at least 
once every 12 weeks during treatment.
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IIa C
Summary of evidence
• This suggestion was based on the opinion and experi-
ence of the great majority of experts in the panel; no 
specific evidence was found. The objective is to mon-
itor treatment effectiveness and improve adherence.
Initial glucose lowering therapy in treatment‑naïve 
patients with type 2 diabetes mellitus (T2DM) (Fig. 1)
5. Lifestyle modification is recommended during all 




• Lifestyle measures should be recommended uni-
versally as the basis for diabetes treatment, as sus-
tained remission of T2DM is related to the degree 
of weight loss. The DIRECT study [7] was an open-
label, cluster-randomized, controlled trial conducted 
at primary health care units in the UK which rand-
omized overweight/obese patients recently diag-
nosed with T2DM to an integrated structured weight 
management program (intervention) (n = 149) or 
the standard of care in accordance with UK guide-
lines (n = 149). The intervention included with-
drawal of antidiabetic drugs, total diet replacement 
(825–853  kcal/day formula diet for 12–20  weeks) 
and stepped food reintroduction (2–8  weeks), fol-
lowed by structured support for weight-loss main-
tenance. The main outcome was weight loss of at 
least 15  kg and remission of T2DM, defined as an 
 HbA1c < 6.5% after withdrawal of antidiabetic agents 
at 12 and 24 months. At 24 months, 11% of patients 
in the intervention group and 2% of controls had 
achieved weight loss of at least 15 kg (OR: 7.49; 95% 
CI 2.05 to 7.32; p = 0.0023), and remission of diabe-
tes was seen in 36% in the intervention group and 
3% in the control group (OR: 25.82; 95% CI 8.25 to 
80.84; p < 0.0001). On post hoc analysis, among those 
MONOTHERAPY:
METFORMIN INSULIN BASED THERAPY ***
HbA1c 6.5%-7.5%                                HbA1c 7.5-9.0%                             HbA1c >9.0%                  HbA1c >9.0% + Symptoms
INITIAL TREATMENT
DUAL THERAPY:
METFORMIN + AD1* 
(SGLT2i or GLP1-RA)
ALTERNATIVES:
[METFORMIN+ AD1 + AD]  or [METFORMIN + AD + AD]
Aer clinically stable,  DUAL 
or TRIPLE therapy should be 
considered.
T2DM WITHOUT CARDIOVASCULAR OR RENAL COMPLICATIONS
QUADRUPLE THERAPY:
METFORMIN + SGLT2 + GLP1-RA + AD **
If HbA1C above the target:





[MET+ PIO] or [MET + SU] or [MET + DPP4i]
TRIPLE-THERAPY:
METFORMIN + SGLT2i + GLP1-RA
ALTERNATIVES:
[METFORMIN+ AD1*+AD+AD] or [METFORMIN+AD+AD+AD] 
or [METFORMIN + INSULIN BASED TREATMENT] 












METFORMIN + AD1* or
INSULIN  BASED THERAPY***
Fig. 1 Decision support algorithm for treatment of hyperglycemia in the non‑pregnant adult patient with type 2 diabetes mellitus
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patients who maintained at least 10  kg of weight 
loss (24% of those in the intervention group), 64% 
achieved remission.
• A meta-analysis [8] of randomized controlled trials 
(RCTs) assessed combinations of structured exer-
cise regimens and physical activity advice with or 
without dietary co-intervention and their effects on 
change in  HbA1c in patients with T2DM. A total of 
47 RCTs (duration ≥ 12  weeks) were included, for 
a total of 8538 patients. Structured exercise train-
ing was associated with a 0.67% reduction in  HbA1c 
(95% CI − 0.84 to − 0.49%) versus control. Structured 
exercise duration of > 150  min/week was associated 
with  HbA1c reductions of 0.89%. A combination of 
physical activity advice and dietary co-intervention 
was associated with a − 0.58% reduction in  HbA1c 
(95% CI − 0.74% to − 0.43%) compared with control.
6. In treatment-naïve, non-pregnant adults recently 
diagnosed with T2DM, without cardiovascular or 
chronic renal disease, in whom HbA1c is 6.5–7.5%, 
METFORMIN monotherapy is recommended to 




• Metformin is the first-line agent of choice for treat-
ment of T2DM, given its established efficacy, safety 
profile, low incidence of hypoglycemia and low cost. 
The efficacy of metformin in reducing diabetes-
related outcomes was demonstrated in overweight 
and obese patients in the UKDPS 34 trial [9]. The 
objective of UKPDS 34 was to investigate whether 
intensive blood-glucose control (treating to a fast-
ing blood glucose of 108 mg/dL) with metformin, a 
sulfonylurea or insulin had any specific advantage 
or disadvantage. In a randomized controlled clini-
cal trial, of 4075 patients recruited to UKPDS, 1704 
overweight patients with newly diagnosed T2DM 
(with baseline fasting blood glucose 110–270  mg/
dL) were assigned to either conventional treatment 
with diet alone (n = 411), intensive control with met-
formin (n = 342) or intensive control with a sulfony-
lurea or insulin (n = 951). The median duration was 
10.7 years. The primary outcome measures were: any 
diabetes-related clinical endpoint, diabetes-related 
death, and all-cause mortality. Overall mean  HbA1c 
at baseline was 7.2 ± 1.5%. Compared with the con-
ventional group, patients in the metformin group 
had risk reductions of 32% (95% CI 13–47, p = 0.002) 
for any diabetes-related endpoint, 42% for diabetes-
related death (9–63, p = 0.017), and 36% for all-cause 
mortality (9–55, p = 0.011). Among patients allo-
cated to intensive blood glucose control, metformin 
showed a greater effect than chlorpropamide, glib-
enclamide, or insulin for any diabetes-related end-
point (p = 0.0034), all-cause mortality (p = 0.021), 
and stroke (p = 0.032). Intensive glucose control with 
metformin decreased the risk of diabetes-related 
endpoints in overweight diabetic patients, and was 
associated with less weight gain and fewer hypogly-
cemic attacks than are insulin and sulfonylureas. It is 
thus the first-line pharmacological therapy of choice 
in these patients.
• Important note: This panel strongly recommends 
that, before initiating any treatment with antidia-
betic agents, the eGFR should be estimated in every 
patient and the drug initiated only if in accordance 
with the product label. In the case of metformin, it 
should not be initiated when eGFR is below 45 mL/
min/1.73  m2 and should be discontinued whenever 
eGFR is below 30 mL/min/1.73 m2, due to the risk of 
metabolic acidosis.
7. In treatment-naïve, non-pregnant adults recently 
diagnosed with T2DM, without cardiovascular or 
chronic renal disease, in whom HbA1c is 6.5–7.5%, 
DUAL THERAPY, including metformin plus a DPP4i, 




• The VERIFY study [10] was a randomized, multi-
center, double-blind, parallel-group trial of newly 
diagnosed patients aged 18–70 years, diagnosed with 
T2DM within 2 years of enrollment, with  HbA1c lev-
els between 6.5 and 7.5%. Patients were randomized 
to “early combination treatment” (metformin and 
vildagliptin) or “standard care” (metformin mono-
therapy plus placebo). If  HbA1c did not remain below 
7.0% with initial treatment, patients in the metformin 
group were crossed over to vildagliptin instead of 
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placebo, entering phase 2 of the study, during which 
all patients were given combination therapy. The pri-
mary efficacy endpoint was “time to initial treatment 
failure”, defined as  HbA1c ≥ 7.0% at two consecutive 
scheduled visits 13  weeks apart from randomiza-
tion. A total of 2001 participants were randomized. 
The relative risk for time to failure was significantly 
lower in the early combination treatment group over 
the 5-year study period (HR 0.51; 95% CI 0.45 to 0.58; 
p < 0.0001). Both strategies were safe and well-toler-
ated. In patients with newly diagnosed T2DM, early 
intervention with combination therapy (metformin 
plus a DPP4i) appears to provides greater long-term 
glycemic control than metformin monotherapy. It is 
important to highlight that this benefit is restricted to 
delay treatment failure of glycemic control.
8. In treatment-naïve, non-pregnant, asymptomatic 
adults recently diagnosed with T2DM in whom HbA1c 
is 7.5% to 9.0%, DUAL THERAPY is recommended to 
improve blood glucose control.
I A
Summary of evidence
• The efficacy and safety of multiple dual therapies were 
compared with those of monotherapies in a meta-
analysis of drug-naïve T2DM patients [11]. A total 
of 36 clinical trials in T2DM, longer than 12 weeks, 
in which initial therapy with two antidiabetic agents 
were compared to one agent were included. The pri-
mary endpoint was the change in  HbA1c from base-
line. Compared with metformin monotherapy, an 
initial combination of DPP4i and metformin was 
associated with a significant decrease in  HbA1c by 
weighted mean difference (WMD − 0.44%, 95% CI 
− 0.57 to − 0.31, p < 0.001), without any increase 
in hypoglycemia nor in serious adverse effects, but 
with a small increase in body weight (WMD 0.38 kg, 
p < 0.001). Compared with metformin monother-
apy, initial treatment combination of a sulfonylu-
rea plus metformin resulted in significant decreases 
in  HbA1c (WMD − 0.68%, 95% CI − 0.86 to − 0.50, 
p < 0.001); however, it significantly increased the risk 
of hypoglycemia (RR 8.91, p = 0.02). Compared with 
metformin alone, initial combinations of a thiazoli-
dinedione (TZD) plus metformin led to significant 
decreases in  HbA1c (WMD − 0.44%, 95% CI − 0.68 to 
− 0.19, p < 0.001) but also significantly increased the 
risk of hypoglycemia (RR 1.60, p = 0.03). Compared 
with metformin monotherapy, initial combinations of 
SGLT2i plus metformin led to significant decreases 
in  HbA1c (WMD − 0.47%, 95% CI − 0.58 to − 0.37, 
p < 0.001), but increased the risk of drug-related AEs 
(RR 1.45; p = 0.004). Compared with monotherapy, 
all initial combination therapies resulted in sig-
nificantly reduced  HbA1c levels in treatment-naïve 
T2DM. Compared with metformin monotherapy, 
the initial combination of DPP-4i and metformin or 
SGLT2i plus metformin was associated with similar 
risks of hypoglycemia, but the initial combination 
therapies of sulfonylurea plus metformin and TZD 
plus metformin increased the risk of hypoglycemia.
• This panel recommends clinical judgment for choos-
ing the appropriate drug, considering the level of 
 HbA1c, the risk of hypoglycemia, tolerability and 
availability.
9. In treatment-naïve, non-pregnant, asympto-
matic adults recently diagnosed with T2DM without 
overt CVD or renal disease, DUAL THERAPY with 




• Concerning renal protection with SGLT2i, the best 
evidence in T2DM with preserved renal function 
comes from the meta-analysis conducted by Neuen 
et al. [12]. This meta-analysis assessed the effects of 
SGLT2i on major kidney outcomes in patients with 
T2DM at different levels of GFR and determined the 
consistency of effect size across randomized clini-
cal trials that reported effects on major kidney out-
comes. The primary outcome was the composite 
of dialysis, transplantation, or death due to kidney 
disease. The authors used random-effects mod-
els to obtain summary relative risks (RRs) with 95% 
CIs and random-effects meta-regression to explore 
effect modification by subgroups of baseline GFR, 
albuminuria. Four studies met the inclusion crite-
ria: EMPA-REG OUTCOME, CANVAS Program, 
CREDENCE and DECLARE–TIMI 58. From a total 
of 38,723 participants, 252 required dialysis or trans-
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plantation or died of kidney disease, 335 developed 
end-stage kidney disease, and 943 had acute kidney 
injury. SGLT2i reduced the risk of dialysis, trans-
plantation, or death due to kidney disease (RR 0.67, 
95% CI 0.52–0.86, p = 0.0019), an effect consist-
ent across studies  (I2 = 0%,  pheterogeneity = 0.53). In a 
subgroup analysis of patients with preserved eGFR 
(> 90  mL/min/1.73  m2), there were 12,167 patients 
with T2DM and 159 events occurred. The events 
were defined as: substantial loss of kidney func-
tion, end-stage kidney disease, or death due to kid-
ney disease. The risk reduction in this subgroup 
was 0.37 (95% CI 0.21 to 0.63, p < 0.0001;  I2 = 41.8%, 
 pheterogeneity = 0.18). The authors identified a propor-
tional effect of SGLT2i despite attenuation of kidney 
function  (ptrend = 0.073). These data provide indirect 
evidence supporting the use of SGLT2i in prevent-
ing major kidney outcomes in people with T2DM 
independently of baseline renal function, including in 
patients with preserved renal function.
• The SGLT2i trial with the greatest number of patients 
with preserved renal function was the DECLARE 
TIMI 58 trial [13]. This trial randomized 25,698 
patients with T2DM at risk for atherosclerotic cardi-
ovascular disease with GFR > 60 mL/min/1.73 m2 to 
receive either dapagliflozin or placebo for a median 
follow up of 4.2  years. The mean baseline eGFR 
was 85.4  mL/min/1.73  m2. A significant number of 
patients (47.6%) had eGFR > 90 mL/min/1.73 m2 and 
45.1% had eGFR 60–90  mL/min/1.73  m2. Moreo-
ver 70.9% were normoalbuminuric (UACr < 30  mg/
mmol). The secondary renal outcome in DECLARE 
was defined as a composite of 40% decrease in GFR 
to < 60  mL/min/1.73  m2, new end-stage renal dis-
ease, death from renal or cardiovascular causes, and/
or death from any cause. This outcome was reduced 
by dapagliflozin (HR 0.76, 95% CI 0.67 to 0.87, 
p < 0.0001).
• The best evidence for a renal-protective effect of 
GLP-1RA in patients without CKD comes from 
REWIND RENAL [14]. This was a sub-analysis of 
renal outcomes in the REWIND study. REWIND 
RENAL compared dulaglutide and placebo for a 
median follow-up of 5.4 years in a multicenter, ran-
domized, double-blind, placebo-controlled design. 
Originally, REWIND included patients with T2DM 
who had either a history of previous cardiovascular 
events or cardiovascular risk factors, with a large 
proportion of patients having normal renal func-
tion, and the mean GFR was 76.9  mL/min/1.73/
m2. The mean urinary albumin-to-creatinine ratio 
(UACr) was 1.80  mg/mmol (95% CI 0.70 to 6.60). 
Of these patients, 65% had normoalbuminuria, 75% 
had eGFR > 60  mL/min/1.73  m2, and 47.5% had 
both eGFR > 60  mL/min/1.73  m2 and normoalbu-
minuria. The renal component of the microvas-
cular outcome was defined as a composite of first 
occurrence of new albuminuria (UACR > 33.9  mg/
mmol) and/or sustained decline in eGFR of 30% or 
more from baseline and/or onset of chronic renal 
replacement therapy. The renal outcome occurred 
in 17.1% of participants in the dulaglutide group 
versus 19.6% of participants in the placebo group 
(HR 0.85; 95% CI 0.77 to 0.93; p = 0.0004). These 
findings suggest that long-term use of dulaglutide 
was associated with reduced incidence of renal out-
comes and better renal protection in people with 
T2DM without renal disease.
• Further evidence of the renal protective effect of 
GLP-1RA in T2DM without CKD comes from 
LEADER RENAL [15], a sub-analysis of second-
ary renal outcomes from the LEADER trial, an RCT 
comparing liraglutide against placebo, in which 9340 
patients with T2DM were included and followed 
up for 3.8  years. Only 10% had microalbuminuria 
or proteinuria, 34.7% had normal eGFR (> 90  mL/
min/1.73 m2), and 41.7% had only mild loss of renal 
function (GFR 60–89 mL/min/1.73 m2). The second-
ary renal outcome of LEADER—a composite of new-
onset persistent macroalbuminuria, persistent dou-
bling of serum creatinine, end-stage renal disease, or 
death due to renal disease—was observed in fewer 
participants receiving liraglutide versus placebo (HR 
0.78; 95% CI 0.67 to 0.92; p = 0.003). This difference 
was attributable to a lower rate of new-onset persis-
tent macroalbuminuria in the liraglutide group (HR 
0.74; 95% CI 0.60 to 0.91; p = 0.004).
• This panel considered, however, that either an 
SGLT2i or a  GLP1-RA should be used along with 
metformin in DUAL THERAPY. This is due to the 
finding that the majority of patients were on met-
formin in all trials: DECLARE (dapagliflozin), 81% 
[16]; EMPA-REG-OUTCOME (empagliflozin), 73.8% 
[17]; CANVAS (canagliflozin), 77% [18]; LEADER 
(liraglutide), 76% [14]; REWIND (dulaglutide), 81.3% 
[19]; and SUSTAIN-6 (semaglutide), 73% [20]. Thus, 
the panel considered that the effect of these agents in 
the aforementioned trials cannot be dissociated from 
the effects of metformin.
10. In treatment-naïve, non-pregnant, asymptomatic 
adults recently diagnosed with T2DM without overt 
CV disease or renal disease, and in whom HbA1c is 
7.5–9.0%, DUAL THERAPY with metformin plus an 
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• In a meta-analysis [21] of seven randomized clinical 
trials comparing GLP-1RA vs. placebo, CV events 
(3P-MACE) and CV mortality were evaluated. A 
total of 27,977 patients on  GLP1-RA and 28,027 in 
the placebo group were analyzed. For the 3P-MACE, 
the hazard ratio (HR) indicating benefit of GLP-1RA 
was 0.88 (95% CI 0.82 to 0.94, p < 0.0001), with a 
number needed to treat (NNT) of 75 in 3.2 years. For 
cardiovascular mortality, the benefit of GLP-1RA was 
also evident. The HR was 0.88 (95% CI 0.81 to 0.96, 
p < 0.003), and the NNT was 163 in 3.2 years.
• Post-hoc analysis of the LEADER trial [22] found that 
patients without CV events but with subclinical ath-
erosclerosis (i.e., in primary prevention) benefit from 
liraglutide to the same extent as those who have had 
CV events. The panel considered that a large propor-
tion of T2DM patients, even without previous CV 
events, may have significant subclinical atheroscle-
rosis. Thus, it may be reasonable to use GLP-1RA or 
SGLT2i preferentially in high-risk patients.
• In the EXSCEL trial [23], the primary endpoint 
(3P-MACE) occurred in 839 patients receiving 
exenatide once weekly (11.4%; 3.7 events per 100 per-
son-years) versus 905 patients in the placebo group 
(12.2%; 4.0 events per 100 person-years). Exenatide 
was non-inferior to placebo (HR 0.91; 95% CI 0.83 to 
1.00; p < 0.001), but not superior (p = 0.06 for superi-
ority).
• Regarding SGLT2i, a meta-analysis of randomized, 
placebo-controlled trials in patients with T2DM ana-
lyzed the effect of this class on CV outcomes. Three 
trials and 34,322 patients (60.2% with established 
ASCVD) were included. SGLT2i reduced MACE 
by 11% (HR 0.89; 95% CI 0.83 to 0.96; p = 0.0014). 
However, this benefit was only seen in patients with 
ASCVD (0.86; 95% CI 0.80 to 0.93), not in those 
without (1.00; 95% CI 0.87 to 1.16; p = 0.0501 for 
interaction) [24].
11. Whenever an AD1 is not available, in treatment-
naïve, non-pregnant, asymptomatic adults recently 
diagnosed with T2DM without known CV disease or 
renal disease, and in whom HbA1c is 7.5–9.0%, DUAL 
THERAPY including metformin plus any AD is rec-




• Dual-therapy with DPP4i and metformin is effica-
cious and safe. A meta-analysis [25] assessing the 
long-term efficacy and safety of DPP4i combined 
with metformin compared to metformin alone in 
patients with T2DM included seven randomized 
clinical trials lasting at least 24  weeks. The decline 
in  HbA1c was greater with dual therapy. The differ-
ence was − 0.54% (95% CI − 0.63 to − 0.45), with no 
increase in hypoglycemia (HR 0.79; 95% CI 0.48 to 
1.30).
• DPP4i have proven CV safety in the noninferiority 
CV outcome trials (CVOTs): TECOS (sitagliptin) 
[26], EXAMINE (alogliptin) [27], and CARMELINA 
(linagliptin) [28]. One exception is vildagliptin, which 
was not tested for safety in large CVOTs. Although 
the recent VERIFY [10] study indicated no signal 
of harm, it was not powered to detect CV safety. 
In SAVOR TIMI 53 (saxagliptin) [29], however, the 
frequency of HF hospitalization was higher in those 
receiving saxagliptin than in the placebo group.
Adding pioglitazone:
• Pioglitazone efficacy and safety was studied in 
patients with CV disease in the PROactive trial [30]. 
A prospective, randomized controlled trial including 
5238 patients with T2DM who had evidence of mac-
rovascular disease assigned to oral pioglitazone (15 
to 45 mg) (n = 2605) or matching placebo (n = 2633), 
taken in addition to their glucose-lowering drugs. 
The primary endpoint was a composite of all-cause 
mortality, non-fatal myocardial infarction (includ-
ing silent myocardial infarction), stroke, acute coro-
nary syndrome, endovascular or surgical interven-
tion in the coronary or leg arteries, and amputation 
above the ankle. The average time of observation was 
34.5  months. The primary composite endpoint was 
not met (HR 0.90, 95% CI 0.80 to 1.02, p = 0.095); 
however, the main secondary endpoint (a composite 
of all-cause mortality, non-fatal myocardial infarc-
tion, and stroke, that is similar to MACE of more 
recent trials) was (HR 0.84, 95% CI 0.72 to 0.98, 
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p = 0.027). Overall, safety and tolerability were good, 
with no change in the safety profile of pioglitazone 
identified (6% vs. 4% in the pioglitazone and placebo 
groups, respectively, were admitted to hospital due 
to heart failure; mortality rates from heart failure did 
not differ between groups).
Adding sulfonylureas:
• The safety of sulfonylureas in relation to CV out-
comes was recently demonstrated in the CAROLINA 
[31] head-to-head randomized clinical trial (glime-
piride versus linagliptin), in the TOSCA.IT [32] 
head-to-head trial (glimepiride versus pioglitazone), 
and in the ADVANCE [3] trial (gliclazide MR).
• In a meta-analysis of randomized clinical trials [33], 
CV safety was extended to glibenclamide as well. The 
panel considered that sulfonylureas are safe in rela-
tion to CV risk; however, they are associated with 
increased incidence of episodes of hypoglycemia. 
Prescription must thus be individualized for each 
patient. Among the sulfonylureas, gliclazide MR may 
be associated with a lower risk of hypoglycemia [34]. 
In the GUIDE randomized clinical trial, a large-scale 
(n = 845) head-to-head comparison of gliclazide MR 
and glimepiride, hypoglycemia occurred less fre-
quently with gliclazide MR (3.7%) than with glime-
piride (8.9%) (p = 0.003).
12. In treatment-naïve, asymptomatic adults with 
T2DM and no overt CV or renal disease in whom 
HbA1c is > 9.0%, DUAL THERAPY including met-
formin and insulin-based therapy should be consid-
ered to improve blood glucose control.
IIa A
Summary of evidence
• A meta-analysis comparing CV and metabolic out-
comes in insulin-based versus non-insulin-based 
glucose-lowering therapy included 19,300 adult 
patients across 18 RCTs. In 16 trials, insulin had 
superior efficacy in attaining blood glucose con-
trol (HR 0.20; 95% CI 0.28 to 0.11) and was associ-
ated with superior reductions in  HbA1c. There was 
no significant between-group difference in risk of 
death from any cause or CV events. Baseline  HbA1c 
among all included studies ranged from 7.4 to 
9.7%. The risk of hypoglycemia was higher among 
patients receiving insulin (RR 1.90; 95% CI 1.44 to 
2.51). Non-insulin treatment was associated with 
a higher proportion of adverse drug reactions [35] 
(54.7% versus 45.3%, p = 0.044).
• Compared with oral ADs, early intensive insulin 
therapy in patients with newly diagnosed T2DM 
is associated with favorable impact on recovery 
and maintenance of beta-cell function, as well 
as protracted glycemic remission. A multicenter, 
randomized clinical trial compared the effects of 
transient intensive insulin therapy—continuous 
subcutaneous insulin infusion (CSII) or multiple 
daily injections (MDI)—versus oral antidiabetic 
agents on beta-cell function and diabetes remis-
sion. A total of 382 treatment-naïve patients with 
recently diagnosed T2DM were randomized to 
receive insulin or oral hypoglycemic agents for 
rapid initial correction of hyperglycemia. The mean 
 HbA1c at baseline was 9.5–9.8%. Treatment was 
stopped once normoglycemia had been achieved 
and remained stable for 2  weeks; patients were 
then followed on diet and exercise alone. Intrave-
nous glucose tolerance tests were performed and 
glucose, insulin, and proinsulin levels were meas-
ured. The primary endpoint was duration of glyce-
mic remission and remission rate at 1 year. Overall, 
more patients achieved target blood glucose con-
trol in the insulin groups than among those treated 
with oral ADs. The 1-year remission rate was sig-
nificantly higher in the insulin groups (51.1% and 
44.9% versus 26.7% with oral ADs; p = 0.0012). 
Beta-cell function, assessed by the HOMA-B and 
acute insulin response, also improved significantly 
after intensive therapy. The increase in acute insulin 
response was sustained in the insulin groups, but 
had declined significantly in the oral ADs group at 
1 year in all patients who achieved remission [36].
• A meta-analysis of interventional studies to assess 
the effect of short-term intensive insulin therapy on 
the underlying pathophysiological defects of T2DM 
and to identify clinical predictors of remission 
(including HOMA-IR) analyzed 7 randomized and 
non-randomized trials with 839 participants. Pooled 
analysis showed an increase in HOMA-B from base-
line after intensive insulin therapy (1.13, 95% CI 1.02 
to 1.25), as well as a reduction in HOMA-IR (− 0.57, 
95% CI − 0.84 to − 0.29). Four studies assessed gly-
cemic remission (n = 559 participants). The propor-
tion of patients with sustained remission was 66.2% 
at 3 months, 58.9% at 6 months, 46.3% at 12 months, 
and 42.1% after 24  months. The authors concluded 
Page 12 of 30Bertoluci et al. Diabetol Metab Syndr           (2020) 12:45 
that short-term intensive insulin therapy can improve 
underlying pathophysiology in early T2DM [37].
13. In adult patients with T2DM who are symptomatic 
(polyuria, polydipsia, weight loss) and present with 
HbA1c > 9%, insulin-based therapy is recommended to 
improve blood glucose control.
I C 
Summary of evidence
• The panel recommended the use of insulin-based 
therapy in T2DM patients with symptoms of hyper-
glycemia. There is general agreement that insulin-
based therapy is needed when symptoms of insulin 
deficiency are present. This statement is based pri-
marily on the pathophysiology of T2DM, plausibility, 
and clinical experience.
14. In patients with T2DM without cardiovascular 
or renal complications, whose HbA1c remains above 
target despite dual therapy, TRIPLE THERAPY with 
metformin plus two AD1 is recommended to improve 




• The panel considered that, in general, triple therapy 
is effective and safe for improving blood glucose con-
trol. The majority of the cited studies indicate supe-
rior  HbA1c-lowering efficacy with 3 than with 2 anti-
diabetic drugs.
• We found no trials directly comparing additive car-
diovascular risk reduction or renal protection with 
a triple combination of SGLT2i and GLP-1RA plus 
metformin. However, SGLT2i have demonstrated 
reduction of renal outcomes in patients with pre-
served renal function [12], and  GLP-1RA have dem-
onstrated cardiovascular risk reduction in patients in 
primary prevention who had subclinical atheroscle-
rosis [21]. Thus, the panel considered plausible that 
both effects can occur simultaneously with a combi-
nation of the two medications.
• Considering triple therapy with a combination of 
metformin/SGLT2i and GLP-1RA, the AWARD-
10 [38] trial randomized 424 patients who were on 
SGLT2i and metformin to receive dulaglutide 1.5 mg 
(n = 142), dulaglutide 0.75  mg (n = 142), or placebo 
(n = 140). The primary objective was to test for supe-
riority of dulaglutide versus placebo regarding change 
in  HbA1c from baseline at 24  weeks.  HbA1c was 
reduced further in patients receiving all three drugs 
(dulaglutide 1.5  mg: − 1.34%, SE 0.06; dulaglutide 
0.75 mg: − 1.21%, SE 0.06) than in those receiving 2 
drugs (placebo plus metformin/SGLT2i: − 0.54% (SE 
0.06); p < 0.0001). Triple therapy improved blood glu-
cose control significantly, with acceptable tolerability.
• The DURATION-8 study [39] was a 28-week, mul-
ticenter, double-blind, active-control trial of T2DM 
patients with  HbA1c 8–12% who were on metformin 
monotherapy. Patients (n = 695) were randomly 
assigned to receive exenatide plus dapagliflozin, 
exenatide plus placebo, or dapagliflozin plus pla-
cebo. The primary endpoint was change in  HbA1c 
from baseline to week 28. At 28  weeks, the change 
in  HbA1c was − 2.0% (95% CI − 2.2 to − 1.8) in the 
exenatide/dapagliflozin group, − 1.6% (− 1.8 to − 1.4) 
in the exenatide group, and − 1.4% (− 1.6 to − 1.2) in 
the dapagliflozin group. The combination of exena-
tide and dapagliflozin significantly reduced  HbA1c 
from baseline to week 28 compared with exenatide 
alone (− 0.4%; 95% CI − 0.6 to − 0.1; p = 0.003) or 
dapagliflozin alone (− 0.6%; 95% CI − 0.8 to − 0.3; 
p < 0.001), and was well tolerated.
• The combination of empagliflozin and linagliptin was 
examined as a second-line therapy in subjects with 
T2DM inadequately controlled on metformin in a 
double-blind randomized clinical trial [40]. Patients 
were randomized to empagliflozin plus linagliptin 
or each drug alone in different dosages as add-on to 
metformin for 52 weeks. The primary end-point was 
change in  HbA1c from baseline at week 24. At week 
24, decreases in  HbA1c from a baseline of 7.90–8.02% 
were superior with empagliflozin/linagliptin than 
with empagliflozin 25  mg or linagliptin 5  mg alone 
as add-ons to metformin. Overall, 61.8% attained 
 HbA1c < 7% with the combination of empagliflozin 
25  mg/linagliptin 5  mg, while only 32.6% did with 
empagliflozin 25  mg alone (OR 4.2, 95% CI 2.3 to 
7.6, p < 0.001) and 36.1% with linagliptin 5 mg alone 
(OR 3.5, 95% CI 1.9 to 6.4, p < 0.001). Efficacy was 
maintained at week 52. The proportion of subjects 
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with adverse events over 52 weeks was similar across 
treatment arms (68.6–73.0%), with no hypoglycemic 
AEs requiring assistance. The empagliflozin/linaglip-
tin combination as second-line therapy for 52 weeks 
significantly reduced  HbA1c compared with the indi-
vidual components, and was well tolerated.
• In an open-label clinical-trial [41], 106 patients 
recently diagnosed with T2DM were randomized 
to metformin/pioglitazone/exenatide (triple ther-
apy) and 115 to metformin followed by sulfonylurea 
and insulin glargine (conventional therapy) with an 
 HbA1c target of < 6.5% for 2 years. Participants who 
received triple therapy had a greater reduction in 
 HbA1c level than those who received conventional 
therapy (5.95% versus 6.50%; p < 0.001). Despite lower 
 HbA1c, participants on triple therapy experienced a 
7.5-fold lower rate of hypoglycemia than patients on 
conventional therapy. Triple therapy was also asso-
ciated with weight loss versus weight gain in those 
receiving conventional therapy (− 1.2  kg versus 
+ 4.1 kg respectively; p < 0.01).
• A post hoc analysis of three randomized trials of 
sequential or concomitant add-on of dapagliflozin 
and saxagliptin to metformin [42] compared the 
safety of triple therapy (dapagliflozin + saxaglip-
tin + metformin) versus dual therapy (dapagliflo-
zin or saxagliptin + metformin). At 24  weeks, the 
incidence of any adverse events and serious adverse 
events was similar between the triple and dual ther-
apy groups, as well as between the concomitant and 
sequential add-on groups. Urinary tract infections 
were more common in the sequential groups than 
in the concomitant groups; genital infections were 
reported only with sequential add-on of dapagliflozin 
to saxagliptin/metformin. Hypoglycemia occurred in 
< 2.0% of patients across all groups.
• A network meta-analysis [43] compared the efficacy 
of adding a third AD in patients with T2DM not 
well controlled  (HbA1c > 7%) by dual-therapy with 
metformin and a sulfonylurea. The meta-analysis 
included only randomized trials of at least 24 weeks’ 
duration. The primary outcomes were change in 
 HbA1c, change in weight, and frequency of severe 
hypoglycemia. A total of 18 trials involving 4535 
participants, with a mean duration of 31  weeks, 
were included. Compared with placebo, the drug 
classes did not differ regarding effect on  HbA1c 
level, with reductions ranging from − 0.70% (95% CI 
− 1.33% to − 0.08%) to − 1.08% (95% CI − 1.41% to 
− 0.77%). Weight gain was seen with insulin (2.84 kg; 
95% CI 1.76 to 3.90 kg) and with thiazolidinediones 
(4.25  kg; 95% CI 2.76 to 5.66  kg), while weight loss 
was seen with GLP-1RA (− 1.63  kg; 95% CI − 2.71 
to − 0.60  kg). Insulin caused twice as many severe 
hypoglycemic episodes than noninsulin ADs. No 
agent was superior to any other in terms of  HbA1c 
reduction. This meta-analysis did not test SGLT2i.
15. In patients with T2DM without cardiovascular 
or renal complications, whose HbA1c remains above 
target despite triple therapy, QUADRUPLE THER-
APY with metformin, two AD1 and one AD is recom-
mended to improve blood glucose control.
I C
Summary of evidence
• Although this panel did not find evidence for using 
insulin exclusively as a fourth drug in quadruple ther-
apy, there was consensus in the expert opinions for 
its use due to the efficacy and safety of insulin-based 
therapy.
16. In patients with T2DM whose HbA1c remains 
above target despite triple therapy, QUADRUPLE 
THERAPY including combinations of metformin 
plus one AD1 and two AD or even metformin plus 3 
AD or insulin based-therapy should be considered to 
improve blood glucose control.
IIa B
Summary of evidence
• Quadruple therapy was evaluated in an open-label 
observational trial [44] conducted in patients with 
T2DM not controlled  (HbA1c 7.5–12%) despite 
three different antidiabetic agents. The objective 
was to address the effectiveness and safety of add-
ing empagliflozin or insulin glargine as a fourth 
agent in patients already on metformin, glimepiride 
and a DPP4i. A total of 268 patients were included: 
142 on empagliflozin (25 mg/day) and 126 on insu-
lin glargine. After 24 weeks,  HbA1c was significantly 
reduced from baseline by 1.5 ± 1.2% (p < 0.001) in 
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the empagliflozin group and 1.1 ± 1.8% (p < 0.001) 
in the insulin group.
• Adverse effects occurred in 21.1% and 27.0% of 
subjects in the empagliflozin and insulin glar-
gine groups, respectively. Adverse effects lead-
ing to treatment discontinuation were reported 
for 9 patients: 3 (2.1%) in the empagliflozin group 
and 6 (4.8%) in the insulin group. Hypoglycemic 
events were the most common adverse effects in 
both groups, and significantly higher (25.4% vs. 
10.6%, p = 0.001) in the insulin versus empagliflo-
zin groups, respectively. Therefore, quadruple ther-
apy with metformin, a sulfonylurea, a DPP4i and 
SGLT2i may be considered effective and safe for 
treating T2DM.
• In a 26-week open-label trial [45], patients receiv-
ing  GLP1RA therapy (liraglutide once daily or 
exenatide twice daily) plus metformin alone or 
metformin plus pioglitazone and/or a sulfonylurea 
were randomly assigned to receive insulin degludec 
plus liraglutide once daily (n = 292) or to continue 
 GLP1RA therapy and oral ADs at the pre-trial dose 
(n = 146). At 26  weeks, superior  HbA1c reductions 
had been achieved with the insulin degludec/lira-
glutide combination (estimated treatment differ-
ence − 0.94%; p < 0.001).
• An open-label, prospective, 52-week study [46] 
was conducted in T2DM to compare the effective-
ness and safety of adding empagliflozin 25  mg od 
or dapagliflozin 10  mg od as part of a quadruple 
therapy regimen for patients already on metformin, 
glimepiride and DPP4i and still inadequately con-
trolled  (HbA1c 7.5–12.0%). The outcome measure 
was change in  HbA1c. In total, 350 patients were 
enrolled with empagliflozin (n = 176) and dapagli-
flozin (n = 174), respectively. After 52  weeks, both 
groups showed significant reductions in  HbA1c, 
but the reduction was greater in the empagliflozin 
group (p < 0.001). Safety profiles were similar in the 
two groups, demonstrating that quadruple therapy 
can be used effectively in patients with T2DM.
• In a 26-week open-label trial [45], patients receiv-
ing GLP-1RA therapy (liraglutide once daily or 
exenatide twice daily) plus metformin alone or 
metformin plus pioglitazone and/or a sulfonylurea 
were randomly assigned to receive insulin degludec 
plus liraglutide once daily (n = 292) or to continue 
GLP-1RA therapy and oral ADs at the pre-trial dose 
(n = 146). At 26  weeks, superior  HbA1c reductions 
had been achieved with the insulin degludec/lira-
glutide combination (estimated treatment differ-
ence − 0.94%; p < 0.001).
Atherosclerotic cardiovascular disease (ASCVD) (Fig. 2)
Treatment of choice:
17. In patients with T2DM and clinical atheroscle-
rosis (ASCVD), the combination of metformin with 
either an SGLT2 inhibitor or a GLP1-RA (AD1) is 
recommended to reduce cardiovascular events and to 
improve blood glucose control.
I A 
Summary of evidence
• In a meta-analysis [24] of three randomized, placebo-
controlled CVOTs of SGLT2i in patients with T2DM, 
with or without ASCVD, the efficacy outcome was 
the classical 3P-MACE composite. The analysis 
included three trials and 34,322 patients (60.2% with 
established ASCVD). There were 3342 MACE and 
2028 cardiovascular deaths. Overall, SGLT2i reduced 
3P-MACE by 11% (HR 0.89; 95% CI 0.83 to 0.96; 
p = 0.0014). This benefit was driven by the EMPA-
REG-OUTCOME (empagliflozin, HR 0.86, 95% CI 
0.74 to 0.99) and CANVAS PROGRAM (canagliflo-
zin, HR 0.82, 95% CI 0.72 to 0.95) trials. Benefit was 
only seen in the subgroup of patients with ASCVD. 
No heterogeneity in between-study variance was 
found across subgroups (Q = 0.94, p = 0.63,  I2 = 0%). 
No effect was seen in patients without CV disease.
• In the EMPA-REG OUTCOME trial [17], T2DM 
patients with CV disease were assigned to receive 
either 10 mg or 25 mg of empagliflozin or placebo 
once daily. The primary outcome was 3P-MACE; 
CV mortality alone was assessed as a secondary 
outcome. A total of 7020 patients were treated for 
a median time of 3.1  years. 3P-MACE occurred 
in 10.5% in the pooled (10 + 25  mg) empagliflozin 
group and in 12.1% in the placebo group (HR 0.86; 
95% CI 0.74 to 0.99; p < 0.001 for noninferiority, 
p = 0.04 for superiority). CV death rates were lower 
in the empagliflozin group (3.7% versus 5.9%; HR 
0.62; 95% CI 0.49 to 0.77; p < 0.001), corresponding 
to a 38% relative risk reduction.
• In a meta-analysis [21] of seven randomized, pla-
cebo-controlled CVOTs of GLP-1RA enrolling 
a total of 56,004 participants, the overall hazard 
reduction for the primary outcome (3P-MACE) 
was 12% (HR 0.88; 95% CI 0.82 to 0.94; p < 0.0001). 
This benefit was driven by LEADER (liraglutide, HR 
0.87, 95% CI 0.78 to 0.97, p = 0.015); SUSTAIN-6 
(injectable semaglutide, HR 0.74, 95% CI 0.58 to 
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0.95, p = 0.016); HARMONY OUTCOMES (albi-
glutide, HR 0.78, 95% CI 0.68 to 0.90, p < 0.0001); 
and REWIND (dulaglutide, HR 0.88, 95% CI 0.79 
to 0.99, p = 0.026). The overall risk of CV mortality 
was reduced to a similar extent (HR 0.88; 95% CI 
0.81 to 0.96; p = 0.003), with this benefit driven by 
LEADER (liraglutide, HR 0.78, 95% CI 0.66 to 0.93) 
and PIONEER 6 (oral semaglutide, HR 0.49, 95% CI 
0.27 to 0.92, p = 0.021).
• In the LEADER trial [47], 9340 T2DM patients 
were randomized to receive liraglutide or placebo. 
The median follow-up was 3.8  years. Overall, 82% 
of patients had established CV disease (31% with 
previous myocardial infarction, 15% with previous 
stroke, and 38% with a history of revascularization). 
Around 25% of patients had > 50% stenosis of coro-
nary, carotid, or lower-limb arteries. Cardiovascular 
mortality occurred in fewer patients in the liraglu-
tide group (4.7%) than in the placebo group (6.0%) 
(HR 0.78; 95% CI 0.66 to 0.93; p = 0.007). A post 
hoc analysis of the LEADER trial [22] assessed the 
CV outcomes in T2DM patients with or without 
history of myocardial infarction or stroke. Patients 
were stratified into three groups: (1) previous MI or 
stroke; (2) no CV events, but documented subclini-
cal ASCVD; and (3) CV risk factors only. Liraglu-
tide reduced the incidence of 3P-MACE compared 
to placebo in patients with previous CV events 
(15%; HR 0.85, 95% CI 0.73 to 0.99) and in those 
with subclinical ASCVD (14%; HR 0.76, 95% CI 
0.62 to 0.94). Liraglutide did not reduce events in 
patients with CV risk factors alone.
18. In T2DM patients with ASCVD and HbA1c above 
the target despite dual therapy with an AD1 and met-
formin, TRIPLE THERAPY with metformin and a 
combination of two AD1 (SGLT2i and GLP-1 RA) is 




• Studies specifically designed to test whether triple 
therapy can reduce MACE in T2DM patients with 
ASCVD were not found in the literature. However, 
in the EMPA-REG OUTCOME trial [17], 49% of 
patients were on dual therapy before being rand-
ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD)
DUAL THERAPY
METFORMIN + [SGLT2i or GLP1-RA]
TRIPLE THERAPY
METFORMIN + SGLT2i + GLP-1 RA
QUADRUPLE THERAPY
MET+ SGLT2i + GLP1-RA + AD
If HbA1C above the target
If HbA1C above the target
ALTERNATIVE:
[METFORMIN+ AD1 + AD]
ALTERNATIVES:
[METFORMIN + AD1  +  AD  + AD] or [METFORMIN + AD + AD + AD] 
or [METFORMIN + AD1 + INSULIN BASED THERAPY]
Fig. 2 Decision support algorithm for treatment of hyperglycemia in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular 
disease
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omized to empagliflozin. Thus, almost half of patients 
in whom cardiovascular events were significantly 
reduced received triple therapy. Considering the 
robust data in reducing 3P-MACE with both GLP-
1RA and SGLT2i, as described above, this panel con-
sidered that the combination of both SGLT2i and 
GLP1-RA should be preferred among other antidia-
betic agents, as they are also safe and effective for 
reducing blood glucose.
19. In T2DM patients with ASCVD and HbA1c above 
target despite triple therapy, QUADRUPLE THER-
APY in a combination of metformin, two AD1 and 




• Evidence from trials using exclusively quadruple 
therapy in T2DM patients with atherosclerotic cardi-
ovascular disease is lacking. The best evidence avail-
able is described in statement 15 of this guideline, 
referring to quadruple therapy in the general patient 
with T2DM. This panel considered that the afore-
mentioned evidence does overlap with patients with 
ASCVD, as high-risk patients were tested in individ-
ual trials for safety. This panel agrees that quadruple 
therapy is recommended whenever  HbA1c targets are 
not reached despite triple therapy, even in patients 
with ASCVD.
Alternative treatment in patients with ASCVD:
20. Whenever AD1 is unavailable and HbA1c is 
6.5–7.5%, metformin in MONOTHERAPY is rec-
ommended as the initial therapy to improve blood 
glucose control and reduce cardiovascular events 




• A meta-analysis of clinical trials and observational stud-
ies [48] assessed the impact of metformin versus placebo 
and active comparators on mortality and cardiovascu-
lar events among T2DM patients, including sub-groups 
with coronary artery disease (CAD), to evaluate death 
from all causes, CV death, and incidence of CV events. 
The meta-analysis included 1,066,408 patients across 
40 studies. Death from CV causes, death from any 
cause, and incidence of CV events were reduced among 
patients with CAD who received metformin, with HR 
0.81 (95% CI 0.79 to 0.84, p < 0.00001); HR 0.67 (95% 
CI 0.60 to 0.75, p < 0.00001); and HR 0.83 (95% CI 0.78 
to 0.89, p < 0.00001), respectively. A subgroup analysis 
showed that metformin reduced mortality from any 
cause in patients with a history of myocardial infarction 
(HR 0.79; 95% CI 0.68 to 0.92; p = 0.003) and in those 
with heart failure (HF) (HR 0.84; 95% CI 0.81 to 0.87). 
The incidence of CV events was also reduced among 
those with HF (HR 0.83; 95% CI 0.70 to 0.98).
Alternatives to AD1 in patients with ASCVD:
21. Whenever an AD1 is unavailable and HbA1c is 
above 7.5%, despite metformin monotherapy, DUAL 
THERAPY with metformin and any AD is recom-
mended to improve blood glucose control in patients 
with T2DM and clinical atherosclerosis (ASCVD).
I A 
Summary of evidence
• The efficacy and safety of DPP-4i and pioglitazone in 
improving hyperglycemia in patients with ASCVD 
is well established in the TECOS (sitagliptin) [26], 
SAVOR-TIMI 53 (saxagliptin) [32], CARMELINA 
(linagliptin) [28], and PROactive (pioglitazone) [30] 
trials. The efficacy and safety of sulfonylureas in 
patients with ASCVD were confirmed in CARO-
LINA (glimepiride) [31], TOSCA.IT (glimepiride) 
[32], and ADVANCE (gliclazide MR) [3], as well as in 
a meta-analysis of clinical trials [35].
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22. Alternatively, if only one AD1 is available and 
HbA1c is above 7.5% despite dual therapy in T2DM 
patients with ASCVD, TRIPLE THERAPY with 
metformin plus an AD1 and any other AD is recom-
mended to improve blood glucose control.
I C
Summary of evidence
• A network meta-analysis of 176,310 participants 
across 236 trials [49] found that SGLT2i and GLP-
1RA were associated with significantly lower rates 
of death from any cause as compared to control. 
SGLT2i (absolute risk reduction − 0.9%; HR 0.78; 
95% CI 0.68 to 0.90) and GLP-1 agonists (absolute 
risk reduction, − 0.5%; HR 0.86; 95% CI 0.77 to 
0.96) were associated with lower mortality, while 
DPP4i were not associated with significant reduc-
tions in death from any cause (absolute risk reduc-
tion, 0.1%; HR, 1.02; 95% CI 0.94 to 1.11). Mortality 
was lower in patients receiving SGLT2i or GLP-1RA 




23. In patients with T2DM and heart failure (HF) with 
reduced ejection fraction (< 40%), combined therapy 
including metformin and an SGLT-2i is recommended 
to reduce cardiovascular mortality, HF hospitaliza-
tions, and to improve blood glucose control.
I A 
Summary of evidence
• In a systematic review and meta-analysis [24] of three 
randomized, placebo-controlled CVOTs of SGLT2i 
in 34,322 patients with T2DM, SGLT2i reduced the 
risk of CV death or HF hospitalization by 23% (HR 
0.77; 95% CI 0.71 to 0.84, p < 0.0001), with a similar 
benefit in patients with and without a history of HF. 
The magnitude of benefit depended on with baseline 
renal function; greater reductions in HF hospitali-
zation (p = 0.0073 for interaction) and lesser reduc-
tions in progression of renal disease (p = 0.0258 for 
interaction) were observed in patients whose kidney 





METFORMIN + SGLT2i + GLP-1 RA
QUADRUPLE THERAPY
MET+ SGLT2i + GLP1-RA + AD*
If HbA1C above the target
If HbA1C above the target
ALTERNATIVE:
[MET+ SGLT2i + AD*]
ALTERNATIVES:
[MET+ SGLT2i + AD + AD*] or [MET + SGLT2i + INSULIN]
* Avoid pioglitazone, saxaglipn or aloglipn.
Fig. 3 Decision support algorithm for treatment of hyperglycemia in patients with type 2 diabetes mellitus and heart failure
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reduce the rate of hospital admission for HF regard-
less of existing ASCVD or history of HF.
• The DAPA-HF clinical study [50] randomized 4744 
patients with symptomatic HF with reduced ejec-
tion fraction (HfrEF) to receive dapagliflozin 10  mg 
once daily or placebo. The primary endpoint was CV 
death or HF events (hospitalization or urgent visit for 
HF). Secondary endpoints were hierarchically tested 
in sequence: composite of CV death or hospitaliza-
tion for HF; composite of recurrent hospitalizations 
for HF or CV death; change from baseline in total 
Kansas City Cardiomyopathy Questionnaire (KCCQ) 
symptom score at 8 months; composite of ≥ 50% sus-
tained decline in GFR, end-stage renal disease, or 
renal death; and death from any another cause. Dapa-
gliflozin reduced the primary endpoint of CV death 
or HF events by 26% (11.6% vs. 15.6%; HR 0.74, 95% 
CI 0.65 to 0.85, p < 0.0001) after a mean follow-up of 
18  months. All components of the first composite 
endpoint contributed to the treatment effect, and the 
effects were generally consistent across subgroups, 
including patients with T2DM and those without 
diabetes (p = 0.7965 for interaction).
• A prospective observational study [48] was con-
ducted to assess the effect of starting metformin 
on the prognosis of patients with newly diagnosed 
HF and new-onset T2DM treated with a “con-
temporary medical regimen” for 9  years. A total 
of 1519 patients were enrolled; mean age was 
71  years, 53.8% were women, and 51.3% had pre-
served systolic function. Over a median follow-up 
of 57 months, 1045 patients (68.8%) died and 1344 
(88.5%) were hospitalized for decompensation of 
HF. There were no cases of lactic acidosis attribut-
able to metformin use. Metformin was associated 
with decreased mortality (HR 0.85, 95% CI 0.82 to 
0.88), largely driven by a lower CV mortality (HR 
0.78, 95% CI 0.74 to 0.82), as well as a lower hospi-
talization rate (HR 0.81, 95% CI 0.79 to 0.84). Nev-
ertheless, metformin was not associated with an 
improved prognosis of HF in patients with a mean 
 HbA1c ≤ 7.0%.
• In all three CVOTs of SGLT2i (EMPA-REG OUT-
COME, CANVAS, and DECLARE-TIMI 58), met-
formin was the cornerstone of treatment, in 74%, 
77%, and 82% of patients, respectively. Considering 
that SGLT2i was used as an add-on to metformin, 
this panel considered that the effects of SGLT2i can-
not be separated from that of metformin. Therefore, 
dual therapy is recommended in treatment-naïve 
T2DM patients with HF [16–18].
24. In patients with T2DM and HF with reduced 
ejection fraction (< 40%) whose HbA1c is above tar-
get despite dual therapy with metformin and an 
SGLT2i, TRIPLE THERAPY by adding a GLP-1RA 




• A meta-analysis of seven randomized placebo-con-
trolled trials [21], including 56,004 high-risk patients 
with T2DM, reported the effects of GLP-1RA on 
hospital admission for HF as a secondary outcome. 
GLP-1RA treatment reduced HF admissions by 9% 
(HR 0.91, 95% CI 0.83 to 0.99; p = 0.028). The reduc-
tion was not robust; the number needed to treat 
(NNT) was 312 (95% CI 165 to 2810) over 3.3 years. 
Although an additive effect of SGLT2i and GLP-1-RA 
in reducing cardiovascular outcomes has not yet 
been proved, this panel considered that, if further 
improvement of blood glucose control is needed, 
adding a GLP-1RA may be plausible and interesting 
in T2DM patients with HF.
25. In T2DM patients with low ejection-fraction HF 
and HbA1c above target despite triple therapy, QUAD-
RUPLE therapy including metformin, an SGLT2 
inhibitor, a GLP-1 RA and a fourth antidiabetic agent 
(AD) or insulin-based therapy is recommended to 
improve blood glucose control.
I C 
Summary of evidence
• Evidence referring exclusively to use of quadru-
ple therapy in patients with T2DM and HF was not 
found in the literature. The best evidence available 
is described in statement 15 of this guideline, refer-
ring to quadruple therapy for the general patient with 
T2DM. This panel agrees that quadruple therapy 
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is recommended whenever  HbA1c targets are not 
reached despite triple therapy, even in patients with 
ASCVD. However, based on expert opinion, a combi-
nation of agents with proven CV safety (i.e., which do 
not increase risk of HF) is reasonable.
26. Saxagliptin, alogliptin, and pioglitazone are not 
recommended as AD in patients with HEART FAIL-




• In the SAVOR-TIMI 53 noninferiority trial [29], 
T2DM patients at risk of CV events were randomly 
assigned to receive saxagliptin or placebo, and fol-
lowed for a median of 2.1 years. The primary efficacy 
and safety endpoint was the classic 3P-MACE. Of 
16,492 patients randomized, more were hospitalized 
for HF in the saxagliptin group than in the placebo 
group (3.5% versus 2.8%; HR 1.27; 95% CI 1.07 to 
1.51; p = 0.007). The number needed to harm (NNH) 
was 143, with HF occurring early in the first year of 
treatment. Patients with high NT-proBNP levels, 
CKD, or previous HF were at increased risk.
• In the EXAMINE [51] noninferiority trial, patients 
with T2DM having experienced acute coronary syn-
drome in the previous 15 to 90 days were randomly 
assigned to receive alogliptin or placebo plus stand-
ard care for T2DM and CV disease prevention. The 
prespecified exploratory endpoint was an extension 
of MACE: all-cause mortality, non-fatal myocardial 
infarction, nonfatal stroke, urgent revascularization 
due to unstable angina, and hospital admission for 
HF. Overall, 5380 patients were assigned to alogliptin 
(n = 2701) or placebo (n = 2679), and followed for a 
median of 533 days. The endpoint occurred in 16.0% 
of patients in the alogliptin group versus 16.5% in the 
placebo group (HR 0.98, 95% CI 0.86 to 1.12). HF-
related hospitalization was the first event in 3.1% of 
patients taking alogliptin versus 2.9% in the placebo 
group (HR 1.07, 95% CI 0.79 to 1.46). This similar 
event rate notwithstanding, the panel recommends 
that alogliptin be avoided in patients with established 
HF.
• A systematic review and meta-analysis [52] of seven 
double-blind RCTs compared the risk of develop-
ment of HF in patients given thiazolidinediones 
(either rosiglitazone or pioglitazone) versus controls. 
The main outcome was development of congestive 
HF and risk of CV death. Of 20,191 included patients 
with either prediabetes or T2DM, 360 developed 
congestive HF events (214 in thiazolidinediones and 
146 on comparators), which suggested a class effect 
of thiazolidinediones. Compared with controls, 
patients given these agents had increased risk of 
developing HF across a wide background of cardiac 
risk (relative risk 1.72, 95% CI 1.21 to 2.42, p = 0.002). 
Conversely, the risk of CV death was not increased 
with thiazolidinediones (RR 0.93, 95% CI 0.67 to 1.29, 
p = 0.68).
• The PROactive Study [30] was a prospective rand-
omized clinical trial of 5238 patients with T2DM and 
macrovascular disease. Patients were randomized to 
receive pioglitazone or placebo. The primary end-
point was an expanded MACE composite including 
death from any cause, nonfatal myocardial infarc-
tion, stroke, acute coronary syndrome, endovascular 
or surgical intervention in the coronary circulation 
or lower-limb arteries, and above-ankle amputa-
tion. The mean observation time was 34.5  months. 
The primary endpoint occurred similarly in patients 
in the pioglitazone group and patients in the pla-
cebo group (HR 0.90, 95% CI 0.80 to 1.02, p = 0.095). 
Patients receiving pioglitazone experienced more HF 
episodes than on placebo (11% versus 8%, p < 0.0001). 
There was also a higher number of HF episodes not 
needing hospital admission (5% vs. 3%; p = 0.003) and 
HF episodes requiring hospital admission (p = 0.007) 
in pioglitazone-treated patients versus placebo. How-
ever, there was no difference in the rate of fatal HF.
Alternative treatment:
27. In T2DM patients with low ejection-fraction HF 
and HbA1c above target despite dual therapy with 
METFORMIN and an SGLT2 inhibitor, the institu-
tion of TRIPLE THERAPY by adding (alternatively to 
GLP1-RA) an AD or insulin-based therapy is recom-
mended to improve blood glucose control.
I A 
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Summary of evidence
Adding a sulfonylurea:
• In the UKPDS trial [53], HF rates were not 
increased among patients who received sulfonylu-
reas as compared with the conventional treatment 
group (3.0% vs. 3.3%, HR 0.91, 95% CI 0.54 to 1.52).
• An observational study [54] investigated all-cause 
mortality associated to sulfonylureas (SU) in patients 
with HF. Patients who were hospitalized for the first 
time due to HF in 1997–2006, alive 30 days after dis-
charge, and on monotherapy with a specific type of 
SU were followed for a mean of 744 days. There were 
1097 patients on glimepiride; 1031 on glibenclamide; 
557 on glipizide; 251 on gliclazide; and 541 on tolbu-
tamide. During the observation period, 2242 patients 
(64%) died. Compared to gliclazide, which was con-
sidered the reference, the risk of death was similar 
among all types of SU: glimepiride (HR 1.10, 95% CI 
0.92 to 1.33); glibenclamide (HR 1.12, 95% CI 0.93 
to 1.34), glipizide (HR 1.14, 95% CI 0.93 to 1.38) and 
tolbutamide (HR 1.04 (0.85–1.26). Significant differ-
ences in mortality risk among SU in patients with HF 
were deemed unlikely.
Adding insulin:
• Insulin has a dose-dependent anti-natriuretic effect, 
and causes weight gain and mild edema at physi-
ologic concentrations. We found no controlled trials 
addressing safety of insulin in patients with clini-
cally established HF or at high risk of HF. In UKPDS 
33 [2], there was no difference in HF rates between 
patients receiving insulin and those on sulfonylureas.
• Insulin glargine, a long-acting insulin analogue, was 
studied in the ORIGIN trial [55]. A sub-analysis 
showed that insulin glargine has a neutral effect on 
both initial and recurrent hospitalizations for HF. 
The trial randomized 12,537 patients with prediabe-
tes or diabetes to either insulin glargine or placebo. 
All were at high cardiovascular risk. However, people 
with more severe HF—New York Heart Association 
(NYHA) class 3 or 4—were excluded. There were no 
differences between groups in hospitalization for HF 
(HR 0.90, 95% CI 0.77 to 1.05) over the 2.5 years of 
follow-up [56]. The position of this panel is that insu-
lin can be used as a safe option to control blood glu-
cose in patients with HF. However, close monitoring 
is advisable in patients with unstable HF.
Adding a DPP4i:
• The TECOS [26] noninferiority trial was designed to 
assess the efficacy and safety of sitagliptin in 14,671 
subjects with CV disease. The study found that sit-
agliptin did not increase hospitalization for HF as 
compared to placebo (HR 1.00, 95% CI 0.83 to 1.20) 
during a 3-year follow-up period. CV mortality was 
similar between sitagliptin and placebo (22.4% versus 
23.1%), as well as all-cause mortality, after hospitali-
zation (29.8% versus 28.8%).
• CARMELINA [28] was a randomized, placebo-con-
trolled, multicenter noninferiority trial conducted 
among adults with type 2 diabetes to test linagliptin 
(n = 3494) against placebo (n = 3485) as add-on over 
usual care. Hospitalization for HF (an exploratory 
cardiovascular outcome) occurred in 209 of 3494 
patients in the linagliptin group (6.0%) and in 226 of 
DPP4i
BASAL-BOLUS INSULIN THERAPY




Mild to Moderate CKD
eGFR: 30-60 mL/min/1.73m2 or 30-90 mL/min/1.73m2   with albuminuria
METFORMIN + SGLT2i
METFORMIN + SGLT2i + GLP-1 RA or (AD)
MET+ SGLT2i + GLP1-RA (or AD) + (AD or Insulin)
Severe CKD
eGFR: <30 mL/min/1.73m2
CHRONIC KIDNEY DISEASE (CKD)
Fig. 4 Decision support algorithm for treatment of hyperglycemia in patients with type 2 diabetes mellitus and chronic kidney disease
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3485 patients in the placebo group (6.5%). The abso-
lute difference in incidence rate was − 0.27 (95% CI 
− 0.82 to 0.28), which was nonsignificant (HR 0.90; 
95% CI 0.74 to 1.08; p = 0.26).
• We did not find CVOTs conducted to assess the CV 
safety of vildagliptin. However, a retrospective meta-
analysis [57] did not find any significant increase in 
risk of HF in vildagliptin-treated patients.
Chronic kidney disease (CKD) (Fig. 4)
Mild to moderate CKD (eGFR 30–60 mL/min/1.73 m2 
or eGFR 30–90 mL/min/1.73 m2 with albuminuria)
28. In T2DM patients with mild to moderate CKD, 
DUAL THERAPY with metformin and an SGLT2i is 
recommended to attenuate loss of renal function, pre-
vent end-stage renal disease, reduce mortality due to 
renal causes, and to improve blood glucose control.
I A 
Summary of evidence
• The CREDENCE study [58] randomly assigned 
patients with T2DM with  HbA1c 6.5–12% and CKD 
(calculated eGFR 30–90  mL/min/1.73  m2 and albu-
minuria > 300–5000  mg/g) to receive either cana-
gliflozin (100  mg/day) or placebo. Metformin was 
used by 57.8% of patients. A total of 4401 patients 
underwent randomization (mean age 63 years, 33.9% 
female). The mean  HbA1c was 8.3% and the mean 
eGFR was 56.2 mL/min/1.73 m2. CV disease was pre-
sent in 50% of patients. The median urinary albumin 
was 927 mg/g. The primary outcome was a compos-
ite of end-stage kidney disease (dialysis for at least 
30  days, kidney transplantation, or eGFR < 15  mL/
min/1.73 m2 for at least 30 days, doubling of serum 
creatinine from baseline or death from renal of car-
diovascular disease). Over a median follow-up of 
2.62 years, the primary outcome occurred in signifi-
cantly fewer patients in the canagliflozin group than 
in the placebo group (43.2 versus 61.2/1000 patients-
year, respectively; HR 0.70, 95% CI 0.59 to 0.82, 
p = 0.00001).
• In a sub-analysis of EMPA-REG OUTCOME [17], 
4124 T2DM patients with GFR > 30 mL/min/1.73 m2 
were assigned to either empagliflozin or placebo once 
daily. The secondary renal outcomes (all prespecified) 
included incident or worsening nephropathy (pro-
gression to macroalbuminuria, doubling of serum 
creatinine, initiation of renal replacement therapy, 
or renal death) and incident albuminuria. Incident or 
worsening nephropathy occurred in 12.7% of patients 
in the empagliflozin group versus 18.8% in the pla-
cebo group (HR 0.61; 95% CI 0.53 to 0.70; p < 0.001). 
Doubling of serum creatinine occurred in 1.5% of 
patients receiving empagliflozin and in 2.6% of those 
given placebo (a significant relative risk reduction 
of 44%). Renal replacement therapy was initiated in 
0.3% in the empagliflozin group and in 0.6% in the 
placebo group (a 55% lower relative risk). The rate of 
incident albuminuria was similar in the two groups.
• Dapagliflozin can reduce progression of kidney 
disease compared with placebo in T2DM. In the 
DECLARE–TIMI 58 trial [16], T2DM patients 
with ASCVD, multiple risk factors, and creati-
nine clearance of at least 60  mL/min/1.73  m2 
were randomized to receive dapagliflozin or pla-
cebo. The prespecified secondary cardiorenal 
composite outcome was “a sustained decline of 
at least 40% in GFR rate, end-stage renal disease 
(dialysis, kidney transplantation, or confirmed 
sustained GFR < 15  mL/min/1.73  m2), or death 
from renal or CV causes”. The median follow-
up was 4.2  years. At baseline, of 17,160 patients, 
47.6% had eGFR > 90  mL/min/1.73  m2, 45.1% 
had GFR 60–90  mL/min/1.73  m2, and 7.4% had 
GFR < 60 mL/min/1.73 m2. The secondary outcome 
was significantly reduced by dapagliflozin versus 
placebo (HR 0.76, 95% CI 0.67 to 0.87, p < 0.0001). 
After excluding CV mortality, the renal-specific 
outcome had a HR of 0.53 (95% CI 0.43 to 0.66, 
p < 0.0001). The decline in eGFR rate was attenu-
ated in 46% of patients. The risk of ESRD or renal 
death was lower in the dapagliflozin group than in 
the placebo group (0.1% versus 0.3%; HR 0.41, 95% 
CI 0.20 to 0.82; p = 0.012). Both the cardiorenal and 
renal-specific composite outcomes were improved 
by dapagliflozin versus placebo in several prespeci-
fied subgroups, including those defined by base-
line eGFR and presence or absence of established 
ASCVD. The mean decrease in eGFR was greater in 
the dapagliflozin group than in the placebo group 
6 months after randomization; however, this decline 
had equalized by 2 years, and at 3 and 4 years the 
mean decrease in eGFR was less in the dapagliflo-
zin group than in the placebo group. Metformin is 
recommended in T2DM and CKD, as it was used 
by 74% of patients in EMPA-REG OUTCOME trial 
[17], 58% of patients in the CREDENCE study [58], 
76% of participants in CANVAS [18], and 81% of 
participants in DECLARE-TIMI 58 [16]. The panel 
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considered that the effects of SGLT2i in these stud-
ies cannot be dissociated from those of metformin.
• The evidence suggests that metformin can be used 
safely in patients with serum creatinine < 1.5 mg/dL. 
Since serum creatinine may overestimate renal func-
tion, calculation of the estimated GFR is preferred. 
Metformin should not be initiated when eGFR is 
< 45  mL/min/1.73  m2. When eGFR is 45–30  mL/
min/1.73  m2, the dosage should be reduced. Met-
formin should be stopped when eGFR falls below 
30 mL/min/1.73 m2 [59].
• A meta-analysis [12] of RCTs included studies which 
reported the effects of SGLT2i on “major kidney out-
comes” (a composite of chronic dialysis, renal trans-
plantation, or renal death) in people with T2DM. 
Four studies met the inclusion criteria, assessing 
three SGLT2i: empagliflozin (EMPA-REG OUT-
COME), canagliflozin (CANVAS Program and CRE-
DENCE), and dapagliflozin (DECLARE–TIMI 58). 
SGLT2i substantially reduced the risk of dialysis, 
transplantation, or renal death (HR 0.67, 95% CI 0.52 
to 0.86, p = 0.0019). The effect was consistent across 
studies  (I2 = 0%, p = 0.53).
29. In patients with T2DM and mild to moderate CKD 
whose HbA1c remains above the target despite dual 
therapy, TRIPLE THERAPY with metformin, SGLT2i 
and a GLP-1RA is recommended to reduce renal out-




• The LEADER RENAL [15] sub-study was a prespeci-
fied sub-analysis of secondary renal outcomes of the 
original LEADER trial, in which patients were rand-
omized to receive liraglutide or placebo. In this sub-
analysis, the secondary outcome was a composite of 
new-onset persistent macroalbuminuria, persistent 
doubling of serum creatinine, ESRD, or renal death. 
A total of 4668 patients were randomized to liraglu-
tide and 4672 to placebo. Most patients were male 
(64.7%); the mean age was 64.4  years, and 82% had 
CV disease. The mean GFR was 80 mL/min/1.73 m2, 
but 20.7% had GFR 30–59 mL/min/1.73 m2 and 2.4% 
had a GFR < 30  mL/min/1.73  m2. Micro- and mac-
roalbuminuria were present in 26.3% and 10.5% of 
patients, respectively. In 76% of patients, liraglutide 
was used as an add-on of metformin. Fewer patients 
in the liraglutide group experienced a renal outcome 
than in the placebo group (HR 0.78; 95% CI 0.67 to 
0.92; p = 0.003).
• A sub-analysis of the REWIND study [14], comparing 
dulaglutide against placebo in T2DM, was conducted 
to examine secondary renal outcomes. The compos-
ite renal outcome was defined as “development of 
macroalbuminuria (development of UACR > 33.9 mg/
mmol in people with a lower baseline concentration), 
a sustained 30% or greater decline in eGFR, or new 
chronic renal replacement therapy (comprising dialy-
sis or renal transplantation)”. A total of 9901 partici-
pants were randomized (1:1) to receive dulaglutide 
or placebo. The median duration of follow-up was 
5.4 years. The mean  HbA1c was 7.3%, and the eGFR, 
76.9  mL/min/1.73  m2. Around 35% of participants 
had albuminuria and 22.2% had a eGFR < 60  mL/
min/1.73  m2. The renal outcome occurred in 17.1% 
of patients in the dulaglutide group versus 19.6% of 
those in the placebo group (HR 0.85; 95% CI 0.77 to 
0.93; p = 0.0004). The largest effect was seen for new-
onset macroalbuminuria (HR 0.77, 95% CI 0.68 to 
0.87, p < 0.0001). Numeric reductions were also seen 
in sustained decline of 30% or more in eGFR (HR 
0.89, 95% CI 0.78 to 1.01, p = 0.066) and new chronic 
renal replacement therapy (HR 0.75, 95% CI 0.39 to 
1.44, p = 0.39), despite no statistical significance.
• The efficacy of triple therapy in glycemic control 
of T2DM patients with moderate-to-severe CKD 
was evaluated in the AWARD-7 study [60], a mul-
ticenter, randomized, open-label, non-inferiority 
trial designed to compare dulaglutide versus insu-
lin glargine in patients with T2DM who were 
already on insulin plus an oral AD. Approximately 
90% of patients had eGFR between 30 and 60  mL/
min/1.73  m2; 32–39% had microalbuminuria and 
44% had macroalbuminuria. Patients who were on 
insulin or insulin plus an oral AD were randomized 
to receive dulaglutide (1.5 mg or 0.75 mg) or insulin 
glargine. Insulin lispro was also added and titrated. 
The trial lasted 52 weeks. The primary outcome was 
 HbA1c at 26  weeks. Secondary outcomes included 
eGFR and UACr. A total of 577 patients were rand-
omized to dulaglutide and insulin glargine. Dulaglu-
tide produced blood glucose control similar to that 
achieved with insulin glargine and slowed the decline 
in GFR. This study demonstrates that dulaglutide is 
safe and effective in patients with moderate-to-severe 
CKD.
Alternative treatment:
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30. In T2DM patients with mild to moderate CKD 
and HbA1c above target despite dual therapy, TRIPLE 
THERAPY with metformin, SGLT2 and an alternative 




• The efficacy and safety of triple therapy with an AD 
in T2DM with chronic kidney disease was addressed 
in studies using DPP-4, pioglitazone and sulfonylu-
reas.
Adding DPP4i:
• The CARMELINA trial evaluated linagliptin in [28] 
a placebo-controlled, multicenter, non-inferiority 
randomized clinical trial that included 6979 T2DM 
patients with high CV and renal risk. Patients had 
either a GFR between 45 and 75  mL/min/1.73  m2 
along with UACr > 200  mg/g or a GFR between 15 
and 45 mL/min/1.73 m2 regardless of UACr. Around 
40% of patients were on dual therapy at baseline and 
received triple therapy. The median duration of fol-
low-up was 2.2 years. The mean age was 65.9 years, 
mean eGFR was 54.6  mL/min/1.73  m2, and most 
of patients had eGFR between 30 and 60  mL/
min/1.73  m2. Regarding albuminuria, 41.9% had 
UACr 30–300 mg/g and 38% had UACR > 300 mg/g. 
This study evaluated the impact of linagliptin versus 
standard care on incidence of the primary outcome 
(3P-MACE). The primary outcome (CV death, non-
fatal myocardial infarction, or nonfatal stroke) was 
similar in both groups group (HR 1.02, 95% CI 0.89 
to 1.17); however, the outcome was significant for 
non-inferiority, indicating safety (p < 0.001). Consid-
ering the renal outcomes (end-stage renal disease, 
death due to renal failure, or a sustained decrease 
from baseline of at least 40% in eGFR), there were 
also no differences (HR 1.04; 95% CI 0.89 to 1.22; 
p = 0.62). The rates of adverse events, serious adverse 
events, and adverse events leading to discontinuation 
were not different between linagliptin and placebo. 
Linagliptin is considered safe in renal failure.
• The safety of sitagliptin in patients with type 2 dia-
betes and moderate eGFR ≥ 30 to < 50  mL/min or 
severe renal insufficiency eGFR < 30 mL/min/1.73 m2 
including patients with end-stage renal disease 
(ESRD) on dialysis was assessed in a 54-week, rand-
omized, double-blind, parallel-group study, patients 
with baseline HbA1 between 6.5 and 10%. Sitagliptin 
group included 65 patients and placebo 26 patients. 
At 54  weeks, patients continuously treated with sit-
agliptin had a mean change (95% CI) from baseline in 
HbA(1c) of − 0.7% (− 0.9, − 0.4) [61].
• In the COMPOSIT-R clinical trial [62], patients were 
randomized to receive either sitagliptin or dapagli-
flozin. The trial included 614 T2DM patients with 
 HbA1c 7.0–9.5% and chronic kidney disease (eGFR 
60–90  mL/min/1.73  m2), who were on metformin 
alone or metformin plus a sulfonylurea. The mean 
eGFR at baseline was 79.4 ± 11.3  mL/min/1.73  m2. 
Around 30% of patients were on dual therapy (met-
formin plus a sulfonylurea). After 24  weeks, the 
change in  HbA1c from baseline was greater with 
sitagliptin (− 0.51%, 95% CI − 0.60 to − 0.43) than 
dapagliflozin (− 0.36%, 95% CI − 0.45 to − 0.27). The 
difference was − 0.15% (95% CI − 0.26 to − 0.04) 
in favor of sitagliptin (p = 0.006). Overall, adverse 
effects occurred in 48.9% in the sitagliptin group, a 
rate similar to that of the dapagliflozin group (51.9%). 
The incidence of hypoglycemia was 15–16% among 
patients who were on triple therapy including met-
formin plus sulfonylurea plus sitagliptin. No serious 
adverse event or deaths were reported with triple 
therapy.
Adding pioglitazone:
• A meta-analysis [63] evaluated the efficacy and safety 
of thiazolidinediones, including pioglitazone and 
rosiglitazone, in the treatment of T2DM patients with 
renal impairment. Nineteen RCTs were included, 
covering 1818 participants, with a mean age ranging 
from 43.4 to 71.1 years, mean baseline  HbA1c of 6.9 
to 9.2%, and mean follow-up of 24 weeks. Of the 19 
RCTs, one (5.3%) enrolled patients who had under-
gone renal transplantation, five (26.3%) enrolled 
dialysis patients, and 13 (68.4%) included patients 
with mild to moderate renal impairment. Fourteen 
trials (73.7%) used pioglitazone as the intervention, 
four (21.1%) used rosiglitazone, and one (5.3%) used 
both. Thiazolidinediones were not associated with 
increased risk of all-cause mortality (RR 0.40, 95% CI 
0.08 to 2.01) and did not increase the risk of HF (RR 
0.64, 95% CI 0.15 to 2.66,  I2 = 0%); however, they did 
increase the risk of edema significantly as compared 
to control (RR 2.96, 95% CI 1.22 to 7.20).
• A small efficacy and tolerability trial [64] rand-
omized 93 patients with T2DM and CKD (defined 
as eGFR < 60  mL/min/1.73  m2 or albuminuria), of 
whom 30% were stage II, 32% were stage III, and 27% 
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were stage IV, to pioglitazone 15 mg (standard-dose) 
or 7.5 mg (low-dose) for 24 weeks. Efficacy and toler-
ability were assessed. The mean change in  HbA1c did 
not differ between the standard-dose and low-dose 
groups (1.1 ± 1.6 and − 1.4 ± 1.5, p = 0.543, respec-
tively). Standard-dose pioglitazone was associated 
with greater increases in body weight, fat mass, total 
body mass, water, and extracellular water compared 
to the low-dose regimen. Compared to patients in 
the 7.5-mg group, those receiving 15-mg pioglita-
zone experienced significant, though modest, weight 
gain (3.5 ± 3.2 versus 0.2 ± 4.4  kg; mean difference 
between groups, 3.3 kg, 95% CI 1.3 to 5.2). No major 
adverse effects (including hypoglycemia, congestive 
HF, and abnormal liver function) were identified. 
This study indicated that low-dose pioglitazone has 
similar efficacy while promoting less weight gain than 
standard-dose pioglitazone in patients with CKD.
Adding sulfonylureas:
• The safety of sulfonylureas was evaluated in the CAR-
OLINA trial [31], a head-to-head, active-controlled, 
randomized trial that assessed the impact of linaglip-
tin versus glimepiride on CV outcomes in high-risk 
patients (many with chronic kidney disease). The 
eGFR (mL/min/1.73 m2) was 60–89 in 58%, 30–59 in 
19%, and 15–29 in 0.4% of participants. The primary 
outcome was time to first occurrence of a 3P-MACE 
event (CV death, nonfatal MI, or nonfatal stroke), 
with the aim of establishing the noninferiority of lin-
agliptin versus glimepiride. A primary outcome event 
occurred in 356 of 3023 patients (11.8%) in the lina-
gliptin group and 362 of 3010 (12.0%) in the glime-
piride group (HR 0.98, 95.47%CI 0.84–1.14; p < 0.001 
for non-inferiority). Thus, linagliptin met the non-
inferiority criterion but not the superiority crite-
rion (p = 0.76). The incidence of adverse events was 
similar in the linagliptin and in glimepiride groups. 
Hypoglycemia, as expected, was increased in the 
glimepiride group: 10.6% in the linagliptin group and 
in 37.7% in the glimepiride group (HR, 0.23 [95% CI 
0.21–0.26]).
31. In T2DM patients with mild to moderate CKD 
and HbA1c above target despite triple therapy, QUAD-
RUPLE THERAPY including metformin, SGLT2i, 
GLP1-RA and a fourth antidiabetic agent (AD) or 




• Although we did not find significant efficacy evi-
dence for QUADRUPLE therapy in T2DM patients 
with mild to moderate renal failure, the panel con-
sidered that this strategy is necessary to lower blood 
glucose in some patients and is reasonably safe when 
eGFR is between 30 and 90 mL/min/1.73 m2, a stage 
of CKD in which most agents can be used, provided 
that their dosages are adjusted when appropri-
ate. Special attention is warranted with metformin, 
which should be replaced when the eGFR falls below 
30 mL/min/1.73 m2. Sulfonylureas also demand cau-
tion due to an increased risk of hypoglycemia in this 
population.
Adding a DPP4i:
• The CARMELINA trial [28] evaluated exploratory 
outcomes including the progression of albuminuria in 
patients on linagliptin and placebo. Among 6979 par-
ticipants, the mean eGFR was 54.6 mL/min/1.73 m2, 
and 80.1% had a UACR > 30  mg/g. Progression of 
albuminuria (from normo- to micro- or macroalbu-
minuria, or from micro- to macroalbuminuria) was 
less frequent in the linagliptin group (35.3%; 21.4 per 
100 person-years) than in the placebo group (38.5%; 
24.5 per 100 person-years). The absolute difference 
in incidence was − 3.18 (95% CI − 5.44 to − 0.92; HR 
0.86, 95% CI 0.78 to 0.95, p = 0.003).
• Saxagliptin decreased albuminuria in T2DM patients 
with normoalbuminuria, microalbuminuria, and 
macroalbuminuria, regardless of baseline eGFR. 
The SAVOR RENAL analysis [65] studied renal out-
comes in 16,492 patients with T2DM who had been 
randomly assigned to receive saxagliptin or placebo. 
The median duration of follow-up was 2.1 years. At 
baseline, 9696 subjects (58.8%) were normoalbumi-
nuric, 4426 (26.8%) were microalbuminuric (ACR 
30–300  mg/g), and 1638 (9.9%) were macroalbumi-
nuric (ACR > 300  mg/g). Saxagliptin therapy was 
associated with less deterioration in ACR from base-
line at the end of the study (p = 0.021, p < 0.001). At 
2 years, the difference in mean ACR change between 
saxagliptin and placebo was 219.3  mg/g (p = 0.033) 
for an estimated eGFR > 50  mL/min/body sur-
face area (BSA), 2105  mg/g (p = 0.011) for eGFR 
30–50  mL/min/BSA, and 2245.2  mg/g (p = 0.086) 
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for eGFR < 30 mL/min/BSA. Changes in ACR did not 
correlate with changes in  HbA1c. The change in eGFR 
was similar between the saxagliptin and placebo 
arms.
Adding a sulfonylurea:
• The ADVANCE [3] trial randomly assigned 11,140 
patients with T2DM to either intensive or standard 
glucose control, defined as the use of gliclazide MR 
plus other drugs as needed to achieve an  HbA1c 
target < 6.5%. Overall, 1434 of 5571 patients in the 
intervention group (27%) and 1423 of 5569 in the 
standard-of-care group (26.7%) had microalbuminu-
ria at baseline. After a median 5 years of follow-up, 
new-onset microalbuminuria had occurred in 1318 
patients (23.7%) in the intensive group versus 1434 
(25.7%) in the standard-of-care group (HR, 0.91; 95% 
CI 0.85 to 0.98; p = 0.02).
Adding pioglitazone:
• The effect of thiazolidinediones on albuminuria in 
T2DM was evaluated in a meta-analysis [66] of 15 
randomized controlled trials. A total of 2860 T2DM 
patients with baseline normo- or microalbuminuria, 
using both rosiglitazone and pioglitazone compared 
with placebo or other ADs, were evaluated. Overall, 
in participants with normo- and microalbuminuria, 
thiazolidinedione therapy was associated with sig-
nificant reductions in urinary albumin excretion. In 
studies of pioglitazone, the weighted mean difference 
of proportional change between the pioglitazone and 
control groups was 16.2% (95% CI 20.8 to 11.6). The 
overall mean difference of the change in urine UACR 
between the thiazolidinedione and control groups 
was 24.8% (95% CI 39.6 to 10.0]. Thiazolidinedi-
ones, especially pioglitazone, reduce urinary albumin 
and protein excretion significantly in patients with 
T2DM.
Severe CKD (eGFR < 30  mL/min/1.73  m2 and 
hemodialysis)
32. In T2DM patients with severe renal failure and 
HbA1c above target, insulin-based therapy is the rec-
ommended choice to improve blood glucose control. 
I B
Summary of evidence
• Insulin glargine is safe and effective in T2DM 
patients with severe renal failure [67], yielding rapid 
 HbA1c reductions with a stable half-life and longer 
duration of action. In a small non-randomized study, 
89 patients with T2DM and CKD (mean eGFR 
34.1 ± 11.5 mL/min/1.73 m2), who were poorly con-
trolled or experienced frequent hypoglycemia on 
oral ADs or NPH insulin, were prescribed insulin 
glargine at bedtime. The dose was started at 0.1 unit/
kg and titrated to the desired target. At 4 months of 
follow-up,  HbA1c had declined from 8.4% ± 1.6 to 
7.7% ± 1.2 (p < 0.001). Body mass index was unaf-
fected (p = 0.96). Mild symptomatic hypoglycemia 
was experienced by 12.5% of patients. No other 
adverse events were reported.
33. In T2DM patients with severe renal failure and 
HbA1c above target, either a DPP4 inhibitor or a GLP-
1RA (if eGFR 15–30 mL/min/1.73 m2) may be consid-
ered to improve blood glucose control.
IIb B
Summary of evidence
• The DPP4i class (sitagliptin, vildagliptin, alogliptin, 
saxagliptin and linagliptin) was also tested in small 
studies in T2DM patients undergoing hemodialysis, 
and safety should be confirmed in larger studies.
• In a small trial [68], 64 patients with T2DM were 
randomized to sitagliptin (in the reduced dosage 
of 25  mg/daily) and 65 to glipizide 2.5  mg/daily. 
There were 28 patients (43%) with eGFR < 30  mL/
min/1.73 m2. After 54 weeks, the mean reduction in 
 HbA1c level from baseline was 0.72% (95% CI 0.95% 
to 0.48%) in the sitagliptin group and 0.87% (95% CI 
1.11% to 0.63%) in the glipizide group. The incidence 
of symptomatic hypoglycemia was 6.3% in the sitag-
liptin group vs. 10.8% in the glipizide group (differ-
ence, 4.8%; 95% CI 15.7% to 5.6%). Severe hypogly-
cemia did not occur in the sitagliptin group vs. 7.7% 
in glipizide group (difference, 7.8%; 95% CI 17.1% to 
1.9%). Sitagliptin monotherapy was effective and well 
tolerated in patients undergoing hemodialysis.
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• Vildagliptin 50  mg once daily was evaluated in a 
2-year open-label trial [69] including 32 patients with 
T2DM on hemodialysis. Changes in glycated albu-
min (GA) and dry weight were evaluated. GA was 
significantly reduced by 2.6 ± 0.6%, from 22.4 ± 0.6% 
at baseline to 19.8 ± 0.4% at 2  years. After 2  years 
of vildagliptin therapy, 15 (46.9%) of 32 patients 
achieved a GA level of < 20%. Dry weight changed 
slightly, with an increase of 1.3 ± 0.8  kg at 2  years. 
No adverse drug reactions related to treatment with 
vildagliptin were seen.
• In a small non-randomized safety trial [70], 16 
patients with T2DM undergoing hemodialysis 
received alogliptin 6.25  mg for 2  years. Baseline 
serum creatinine was 10.6 ± 1.0 mg/dL. Mean  HbA1c 
dropped from 7.1 to 5.8% after treatment. None of 
the patients exhibited significant adverse effects, such 
as hypoglycemia. One patient experienced a drug-
related rash. Four patients withdrew from this study 
during the treatment period.
• The effects of monotherapy with linagliptin 5 mg in 
21 patients with T2DM undergoing hemodialysis was 
examined in a 6-month non-randomized trial [71]. 
Linagliptin was administered daily. GA dropped from 
21.3% ± 0.6% to 18.0% ± 0.6% over the 6-month treat-
ment period, and body weight did not change. None 
of the patients experienced hypoglycemia.
• Saxagliptin was studied in a sub-analysis of the 
SAVOR-TIMI 53 trial [72] according to baseline 
renal function. Patients with T2DM at risk of car-
diovascular events were stratified by renal function. 
There were 336 patients with severe renal impairment 
(eGFR < 30  mL/min/1.73  m2) who were randomized 
to receive either saxagliptin or placebo. The primary 
endpoint was the time to first event of a composite 
of CV death, myocardial infarction (MI), or ischemic 
stroke. The major secondary endpoint included the 
primary composite plus hospitalization for heart fail-
ure, coronary revascularization, or unstable angina. 
After a median duration of 2  years, saxagliptin did 
not change the risk of the primary and secondary 
composite endpoints compared with placebo, irre-
spective of renal function (p = 0.19 for interactions). 
The relative risk of hospitalization for heart failure 
with saxagliptin was similar (p = 0.43 for interaction) 
in patients with GFR > 50 mL/min/1.73 m2 (HR 1.23, 
95% CI 0.99 to 1.55), GFR 30–50  mL/min/1.73  m2 
(HR 1.46, 95% CI 1.07 to 2.00), and in patients with 
GFR < 30 (HR 0.94, 95% CI 0.52 to 1.71). The median 
 HbA1c at 1  year was lower compared to placebo in 
saxagliptin-treated patients with severe renal impair-
ment (7.1% vs. 7.7%, p = 0.002). At least one adverse 
event occurred in 152 (88%) saxagliptin-treated 
patients with severe renal impairment compared with 
126 (77%) patients treated with placebo (p = 0.006), 
with no significant difference in severe adverse events.
• Data for the use of GLP-1RAs in T2DM with severe 
renal failure (< 30 mL/min/1.73 m2) are derived from 
subsets of larger trials that included a very small 
number of patients, such as 2.5% in LEADER RENAL 
(liraglutide) [15], 2.5% in SUSTAIN-6 (injectable 
semaglutide) [20], and 1% in REWIND RENAL (dula-
glutide) [14]. Thus, data on the safety of GLP-1RA in 
this population is limited.
Conclusions
In non-pregnant adults with type 2 diabetes, the rec-
ommended  HbA1c target is below 7%. Higher levels are 
recommended in frail older adults and patients at higher 
risk of hypoglycemia. Lifestyle modification is recom-
mended at all phases of treatment. In recent diagnosed 
patients without cardiovascular or renal complications, 
metformin in monotherapy is the first choice of treat-
ment when  HbA1c is 6.5–7.5%. Optionally, metformin 
along with a DPP4 inhibitor may be considered to reduce 
failure in controlling blood glucose. When HbA1c is 
7.5–9.0%, dual therapy, including metformin a first line 
antidiabetic drug AD1 (SGLT2i or GLP-1RA) is recom-
mended, due to their cardiovascular and renal benefits. 
If an AD1 is unaffordable, other antidiabetic drugs (AD) 
may be used. Triple or quadruple therapy should be con-
sidered when HbA1c remains above target despite dual 
therapy. In patients with clinical atherosclerosis, the 
combination of metformin plus one AD1 independently 
of HbA1c level is also recommended to reduce cardio-
vascular events. In the stable patient with low ejection 
fraction heart failure (< 40%) and glomerular filtration 
rate (eGFR) > 30  mL/min/1.73  m2, metformin plus an 
SGLT2i is recommended to reduce cardiovascular mor-
tality, heart failure hospitalizations and to improve 
blood glucose control. In patients with mild to moder-
ate diabetes-associated chronic kidney disease (CKD) 
(eGFR  30–60  mL/min/1.73  m2 or eGFR 30–90  mL/
min/1.73  m2 with albuminuria > 30  mg/g), the combi-
nation of metformin and a SGLT2i is recommended to 
attenuate loss of renal function, reduce albuminuria and 
improve blood glucose control. In patients with severe 
renal failure (eGFR < 30 mL/min/1.73 m2), insulin-based 
therapy is recommended to improve blood glucose con-
trol. Alternatively, GLP-1RA, DPP4i, gliclazide MR and 
pioglitazone may also be considered to reduce albu-
minuria. In conclusion, the current evidences support 
individualizing anti-hyperglycemic treatment for T2DM 
according to their cardiovascular and renal status.
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